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 Abstract 
 
 
Aim: To study if the amount of residual medulloblastoma correlates with 
improved survival.  
Material and Methods: Tumour volumes were measured on preoperative and 
immediate postoperative MR scans of 37 children operated on for 
medulloblastoma between 1999 and 2006. The residuum ratio                        
(post-/ preoperative tumour volume) was calculated and correlated to 
mortality and actuarial survival.  
Results: Mean preoperative volume was 32 cm³ (range: 4.43-71.99 cm³, 
median: 30.61 cm³). Mean postoperative volume was 3.3 cm³ (range: 0- 23.3 
cm³, median: 0.99 cm³). Mean residuum ratio was 10.7% (range: 0-74%); 28 
(75.7%) patients had ≤15% residuum. At mean follow-up of 45 months (range: 
6-117), 15 (40.5%) patients had died. Using either the presence of any 
residual tumour or a limit of 15% residuum ratio, there was no statistically 
significant difference in mortality or actuarial 5-year survival (p: 0.27, log 
rank). Also, the difference in 5-year survival of patients with a residual 
tumour > and ≤1.5 cm³ was not statistically significant (log rank, p= 0.367). 
Conclusions: While there is a trend for patients with less residual 
medulloblastoma volume to have better outcome than those with more 
residual medulloblastoma volume, the number of the patients of this pilot 
study was not large enough to reach a conclusion and a larger study is 
required.  
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Chapter 1 
 
1. Introduction  
 
1.1. Historical review 
 
The term medulloblastoma was originally introduced in medical terminology 
by Bailey and Cushing in 1925 (1). They used this term to describe “a very 
cellular tumour of a peculiar kind, apparently arising over the roof of the 
fourth ventricle and projecting into the centre of the cerebellum” (1). The 
tumour tended to involve the fourth ventricle, displayed rapid growth and had 
an extremely bad prognosis. Historically tumours of this histological type had 
been referred by pathologists by various other names including neurocytoma, 
neuroblastoma and sarcoma (2-5).  
 
Cushing had originally termed this tumour ”spongioblastoma cerebelli” (5). 
They had followed Ribbert (6), unaware at the time of preparing their paper 
that Strauss and Globus (7) had previously and independently of Ribbert (6) 
employed the same term. After discussion between themselves, Bailey and 
Cushing adopted the term Medulloblastoma (1). They preferred this term 
because it indicates that the cells represent an embryonic stage earlier than 
either the spongioblast or neuroblast, a stage corresponding to the 
medulloblasts (8). 
 2 
The terminology and the classification of medulloblastoma remained 
unchanged until 1983 when Rorke (9), Becker and Hinton (10) suggested that 
all malignant small cell tumours of central nervous system, including 
medulloblastoma, be classified as primitive neuroectodermal tumours (PNET) 
and be subdivided by location (11).  
 
 
 
1.2. Epidemiology 
 
Medulloblastoma is the commonest type of malignant brain tumour of 
childhood and the second most common overall after astrocytomas (12). It 
constitutes approximately 20% of childhood cerebellar tumours with a male to 
female ratio that ranges from 1.5:1 to 2:1 (12-16).  
 
The overall incidence among children aged 0 to 19 years is 0.63 per 100,000 
person-years or 16% of all paediatric brain tumours in the United States 
(11;12). In childhood the tumour has a bimodal age distribution, with peaks at 
3 to 4 years and at 8 to 9 years (11;16;17). Medulloblastoma in adults is rare, 
accounting for only 1% of all CNS tumours. The incidence is highest between 
the age of 20 to 34 years at 0.21 per 100,000 person-years and reduces to 0.05 
per 100,000 person-years between 55 to 64 years before dropping to zero after 
the age of 64 years (18;19).  
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In their series Chang et al reported that about 55% of tumours originate from 
the vermis, 25% from the cerebellar hemisphere, 3% from the brain stem, and 
an undetermined origin in 17% (20).  
 
 
 
1.3. Cell origin 
 
Medulloblastoma is believed to be derived from the granule-cell progenitors 
which are located in the external granular layer of the cerebellum (21-24). 
This is a germinal zone harbouring actively proliferating progenitor cells 
originating from the rhombic lip during embryonic development (24). The 
external granular layer eventually disappears as all cell division ceases and all 
post mitotic neurons move to the internal granular layer (25).  
 
 
 
1.4. Modern Histopathological Classification  
 
Embryonal (primitive) neuroepithelial neoplasm features include:  
1) Predominance in children 
2) Tendency to disseminate through cerebrospinal fluid pathways 
3) Dominant population of small undifferentiated cells 
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4) High mitotic indices and widespread apoptosis 
5) Potential for divergent neuroepithelial differentiation (26). 
 
In 1983, Rorke (9) and Becker and Hinton (10) noted the histological 
similarity of medulloblastomas and PNETs. They appear as small, round, 
blue-cell tumours with hyperchromatic nuclei, minimal cytoplasm, and 
various degrees of calcification on haematoxylin-eosin stain (Figure 1) (27). 
Microvascular proliferation is relatively uncommon (28). 
 
Histologically, childhood and adult medulloblastoma are identical. They are 
highly cellular, malignant invasive tumours corresponding to WHO 
malignancy grade IV (29).  
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a)  
b)  
c)  
 
Figure 1: Histological features of medulloblastoma: A. Classic medulloblastoma: 
sheets of densely packed cells with round to oval shaped hyperchromatic nuclei 
surrounded by scanty cytoplasm. Cells stained with haematoxylin and eosin. B. 
Desmoplastic medulloblastoma is characterised by nodular reticulin-free zones 
(“pale islands”) surrounded by densely packed, highly proliferative cells, which 
produce a dense intercellular reticulin fibres network. Cells stained with reticulin. 
C. Large cell - Anaplastic medulloblastoma: marked nuclear pleomorphism, cell-
cell wrapping and high mitotic activity. Cells stained with haematoxylin and eosin. 
Photographs courtesy of  Dr Marie-Ann Brundler Consultant Pathologist, 
Birmingham Children’s Hospital, U.K. 
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Based on WHO classification of tumours of the Nervous System (2002), the 
Embryonal Tumours group includes the following types of tumours (29): 
 
Medulloepithelioma  9501/3 
Ependymoblastoma 9392/3 
Medulloblastoma 9470/3 
      Desmoplastic Medulloblastoma 9471/3 
      Large cell Medulloblastoma 9474/3 
      Medullomyoblastoma 9472/3 
      Melanotic Medulloblastoma 9470/3 
Supratentorial primitive neuroectodermal tumour 9473/3 
     Neuroblastoma 9500/3 
     Ganglioneuroblastoma 9490/3 
Atypical teratoid / rhabdoid tumour 9508/3 
 
Macroscopically medulloblastomas are pink or purple coloured tumours. They 
are poorly demarcated with a soft and friable consistency. The tumour may 
extend through the fourth ventricle into the cerebral aqueduct or into the 
cisterna magna via the foramen of Magendie (11). It may invade the 
cerebellum, brainstem, or cerebellar peduncle. Involvement of the cerebellar 
hemispheres is uncommon in children but is more frequent in adults (11). 
Brainstem infiltration occurs in 15% to 36% of cases (11;30). There may be 
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foci of haemorrhage but cysts are unusual. Areas of necrosis may occur but 
are not extensive (11).  
 
Microscopically, differentiated medulloblastomas with neuroblastic features 
are distinguished by Homer Wright rosettes (31). These rosettes are formed by 
cells surrounding fibrillary structures and characteristically do not encircle 
blood vessels (32). Rarely, the tumour grows extra-axially along the cerebellar 
surface without invading adjacent parenchyma (33). Mitoses and apoptotic 
bodies are plentiful in regions where the nuclear to cytoplasmic ratio is high 
(26).  
 
The desmoplastic variant of medulloblastoma is characterized by distinctive 
reticulin-free “islands” of densely packed monomorphic round cells among 
the reticulin-rich area. It is seen in up to 50% of adult cases of 
medulloblastoma compared to 15% in children (33;41). It has a tendency to be 
located within the cerebellar hemisphere and is often firmer in consistency 
and is better demarcated than the classical medulloblastoma as a result of the 
greater connective tissue component of the tumour (34).  
 
Neuronal differentiation is often prominent in nodular medulloblastomas. 
Focal melanin production and evidence of striated muscle differentiation can 
both occur in medulloblastomas creating the variants melanotic 
medulloblastoma and medullomyoblastoma respectively. Nodular 
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medulloblastomas contain centres of dark cells surrounding pale islands, 
analogous to the germinal centers of a lymph node. They are associated with a 
better prognosis compared to that of the classic histological subtypes in 
children (35-37), but the reverse is true  in adults (38). 
 
Large-cell medulloblastoma is another variant of medulloblastoma and has a 
poor prognosis (26). It has recently been characterised as a highly malignant 
variant, which represents about 4% of medulloblastomas (39). Only a few 
cases have been reported in the literature. All patients were male and the age 
of manifestation ranged from 13 months to 4 years (29). Morphologically this 
variant resembles the atypical teratoid / rhabdoid tumours of the cerebellar 
region, but differs on the basis of its immunophenotype and cytogenetic 
features (29).  
 
 
 
1.5. Staging 
 
Medulloblastoma has a strong propensity to metastasize within the 
subarachnoid space due to its tendency to penetrate the ependymal surface 
(28). Metastases may form microscopic deposits, gross nodules, or en plaque 
masses along the brain or spinal cord. An autopsy series revealed that 
cerebrospinal spread occurs in up to 50% of patients (26;40). Extraneural 
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metastasis occurs in approximately 5% of patients and most commonly 
involves the bone marrow (11).  
 
In 1969, Chang et al developed an internationally recognised operative 
staging system for patients with medulloblastoma as clinical staging was 
deemed inaccurate (20). That system was developed with the International 
TNM-staging designation. Since there are no lymphatic channels in the brain, 
they omitted the letter N in their staging system. Their proposed operative 
staging system for cerebellar medulloblastoma is outlined in Table 1 (20). 
 
In 1985, Laurent et al reported a postoperative MAPS (metastasis, age, 
pathology, surgery) classification system (41). The primary purpose of the 
MAPS system was to evaluate the prognostic impact of the extent and degree 
of tumour burden after initial definitive surgery, and to analyze this data in a 
prospective manner. They noted the importance of obtaining enhanced CT 
scans of the brain postoperatively in order to visualize the extent of residual 
tumour as well as intracranial metastasis. They recommended CSF analysis 
(cells, polyamines), CT-myelogram, bone scan, leptomeningeal / bone biopsy 
and CT - metrizimide myelography after surgery, aiming to detect distal 
metastasis (Table 2) (41).  
 
CSF cytology is performed using CSF drained via lumbar puncture because 
this method is more sensitive than the use of ventricular CSF for detecting 
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disseminated disease (42). Lumbar puncture prior to surgical resection 
presents an unacceptable risk of cerebral herniation and should be performed 
after tumour has been resected. However, it should not be performed any 
sooner than 2 weeks postoperatively in order to avoid false positive cytology 
results caused by the liberation of tumour cells during surgery (18;43).  
 
In Chang’s classification (41) the “T” represented the location and size of the 
tumour (20). This was a staging system based on preoperative and 
intraoperative findings and was not related to the postoperative findings. This 
led to confusion in both staging and treatment of these tumours.  
 
Aiming to alleviate this problem, Laurent et al added a surgical “S” 
component in their classification that must be confirmed by a postoperative 
enhanced CT scan of the brain. Stage S3 related to invasion of the brain stem 
structures including the mesencephalon and/or the diencephalon, and/or 
myeloencephalon by the tumour. It remains unclear as to the reason why they 
selected a residual tumour diameter of 1.5 cm as the size to distinguish the 
stage S1 from stage S2 on postoperative CT scan (41).  
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Table 1.  Chang Staging System (20)  
 
T 1: Tumour less than 3 cm in diameter and limited to the classic midline position in   
        the vermis, the roof of the fourth ventricle, and less frequently to the cerebellar 
        hemispheres.  
 
T 2:  Tumour more than 3 cm in diameter, further invading one adjacent structure or  
         partially filling the fourth ventricle.  
 
T3:  It was subdivided into: 
 
T 3a: Tumour further invading two adjacent structures or completely filling the  
          fourth ventricle with extension into the aqueduct of Sylvius, foramen of  
          Magendie, or foramen of Luschka, thus producing marked internal 
          hydrocephalus.  
 
T3b: Tumour arising from the floor of the fourth ventricle or brain stem and filling  
         the fourth ventricle. 
 
T 4: Tumour further spreading through the aqueduct of Sylvius to involve the third      
        ventricle or midbrain, or tumour extending to the upper cervical  cord.  
 
M 0: No evidence of gross subarachnoid or haematogenous metastasis.  
 
M 1: Microscopic tumour cells found in lumbar cerebrospinal fluid. 
 
M 2: Gross nodular seedings demonstrated in the cerebellar, cerebral subarachnoid      
         space, or in the third or lateral ventricles 
 
M 3: Gross nodular seeding in the spinal subarachnoid space 
 
M 4: Extraneuroaxonal metastasis.    
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Table 2.  MAPS Classification System (41) 
 
Metastasis (M) 
M0: No evidence of metastasis  
M1: Cells present in leptomeninges or cerebrospinal fluid 
M2: Nodular seeding demonstrated in the supratentorial compartment  
        (enhanced CT scan) 
M3: Nodular seeding of the spinal compartment (myelogram)  
M4: Combined nodular seeding of two compartments (supratentorial and/or infratentorial  
        and/or spinal)  
M5: Evidence of systemic seeding (bone marrow, various bone and viscera scans) 
 
Age (A) 
A1: >3 years 
A2: <3 years 
 
Pathology (P) 
P1: Microscopic appearance: Benign, classic for tumour type, well-differentiated single     
       cell  line  
P2: Microscopic appearance: Anaplastic, malignant, multiple differentiated cell lines 
 
Surgery (S) 
Postoperative residual tumour was confirmed by enhanced CT scan of the brain 
 
S0: No tumour    
S1: Remaining tumour < 1.5 cm (largest diameter)   
S2: Remaining tumour > 1.5 cm (largest diameter)   
S3: Remaining tumour (any size) invading brain stem structures (medulla oblogata,    
      pons, midbrain, diencephalon)  
S4: Remaining tumour (any size) extending into more than one central nervous system  
      compartment  (supratentorial, infratentorial, spinal compartments)  
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1.6. Prognostic factors  
 
The prognosis of patients with medulloblastoma depends on several factors 
(Table 3). These factors include the presence or absence of metastases at 
diagnosis (44-46), the radiotherapy modality used (45;47), the use of 
chemotherapy (48-51), the extent of the residual tumour (44;46;50;52-55), the 
patient’s gender (50;54), the duration of the symptoms (56), whether a 
ventricular-peritoneal shunt is inserted within 30 days after the surgical 
resection of the tumour (47), [18F] fluorodeoxyglucose uptake during positron 
emission tomography (57) and the genetic and molecular profile of the 
medulloblastoma  (44;58). A short duration of symptoms is associated with 
more advanced medulloblastoma (56). This finding has potentially significant 
implications for the identification of prognostic groups in medulloblastoma as 
well as medicolegal claims of "delay in diagnosis" (56). Dissemination of 
medulloblastoma at diagnosis remains one of the most important clinical 
predictors of outcome (18;59;60). Leptomeningeal metastases have been 
reported to occur in up to 46% of patients in different series but usually range 
from 10% to 35% of cases (61-63). Extra-axial metastases are uncommon at 
initial presentation. Approximately 5% of patients with medulloblastoma may 
be expected to develop systemic metastases (61;64). Extracranial sites of 
spread include the bone, bone marrow, liver, lungs and lymph nodes and are 
usually associated with end stage disease (18;65-67). Rare sites of extracranial 
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metastases which have been anecdotally reported in the literature include 
breast (68) and fibroadenoma of the breast (69).  
 
The importance of the role of surgery in patients with medulloblastoma is 
widely recognised. It reduces the volume of tumour, alleviates brain stem 
compression from the tumour and restores the patency of CSF pathways by 
relieving CSF obstruction at the level of the fourth ventricle. 
Jenkin et al reported that total tumour resection as determined by the surgeon, 
was the most significant favourable prognostic factor. They also noted that 
residual tumour was demonstrable on 54% of post-operative scans and was 
associated with a significantly poorer outcome (70). In contrast, Bourne et al 
reported that the extent of surgical resection as estimated by the neurosurgeon, 
did not significantly influence prognosis. However, they also found that the 
presence of residual contrast enhancement seen on CT scans performed 
immediately postoperatively was associated with a significant decrease in the 
5-year recurrence-free survival rate (71).  
 
Albright et al studied a series of 203 children with medulloblastomas who 
were treated according to the Children's Cancer Group-921 protocol. After 
univariate analysis of data on the extent of primary medulloblastoma excision 
and the extent of the residual tumour, they found that there was no correlation 
between either of these factors as independent variables on progression free 
survival (Table 4) (52).  
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Table 3. Prognostic Factors Associated With Outcome for 
Medulloblastoma (72) 
 
 
 
Increased Survival 
 
Diminished Survival 
 
 
Sex, female (16;54) 
Gross total resection (55) 
No metastasis (55) 
Desmoplastic histology (36) 
Increased apoptosis index (73) 
Hyperdiploidy (74) 
High TrkC expression (75-77) 
Radiotherapy (45;47), Chemotherapy (48-51) 
Long duration of the symptoms (56)  
 
Younger age (78) 
Subtotal resection (55) 
Metastasis (55) 
Insertion of a ventricular-peritoneal 
shunt within 30 days after the surgical 
resection of the tumour (47) 
[18F] fluorodeoxyglucose uptake during 
positron emission tomography (57) 
Large-cell anaplastic histology (39;79) 
Elevated Ki-67 / MIB-1 proliferative 
index (80) 
Aneuploidy (81) 
Elevated ErbB2 expression (44;58) 
Isolated 17p loss of heterozygosity (44;82) 
Elevated expression and amplification of 
c-MYC (83-85) 
Over-expression of calbindin-D28k (86) 
Expression of genes related to cell 
proliferation and metabolism: (MYBL2) 
enolase 1, LDH, HMG1(Y), cytochrome 
C oxidase and multidrug resistance 
(sorcin) (77;87)  
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Table 4.  Extent of Medulloblastoma Resection (52) 
Total                 No visible tumour evident at the completion of resection  
Near-total        >90% resection, but visible tumour remains  
Subtotal           51-90% resection  
Partial              11-50% resection 
Biopsy               ≤ 10% resection  
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However, on multivariate analysis the extent of the residual tumour was found 
to be an important prognostic factor determining outcome in certain children. 
In particular, the extent of residual tumour did correlate with better prognosis 
in children with: 
 
1) No disseminated disease (M0) and <1.5 cm² of residual tumour on 
immediate post-operative CT scan of the brain, and  
 
2) Age more than 3 years with no disseminated disease (M0) at the time of 
diagnosis and with residual tumour <1.5 cm² on immediate post-operative CT 
scan of the brain (52). In that case, the residual tumour was an important 
variable in outcome and one that neurosurgeons can control.  
 
A residual tumour of less than 1.5 cm² is statistically associated with 
improved survival but only in the subset of patients aged 3 years or older in 
whom CT / MRI scanning confirmed M0 disease at diagnosis (3).  
 
The question thus arises of why CT / MRI scan - detectable disease would be 
related to survival, whilst the neurosurgeons’ observations would not? The 
absolute residual tumour burden, which is most likely to be in the range of 1 
billion cells (1 cm³), is the determining factor for the efficacy of 
chemotherapy and radiotherapy rather than the percentage of tumour removed.   
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Zeltzer et al reported that the progression free survival distributions at 5 years 
for patients with non-metastatic disease and <1.5 cm² of residual tumour on 
the immediate postoperative CT / MRI scan (within six days after the primary 
operation), versus ≥1.5 cm² of residual tumour by scan, were significantly 
different (p= 0.023; 78%+/-6% v 54%+/-11%, respectively) (55). There is 
however no clear rationale behind the selection of 1.5 cm² as a cut off point 
for the size of residual tumour on immediate postoperative CT or MRI scans 
of the brain.   
 
The significance of total medulloblastoma excision was demonstrated in the 
SFOP trial for young children (less than 5 years of age) with non-metastatic 
disease (88). In that trial, it was shown that cure was possible with 
conventional chemotherapy alone in children with non-metastatic 
medulloblastoma who underwent gross total resection confirmed by early 
radiological assessment, but is not sufficient in isolation for treatment of those 
with metastatic or incompletely resected medulloblastoma (88).  
 
In the BBSFOP protocol, children who had no postoperative radiological 
residual disease and no metastasis had a 73% 5-year survival, and most 
children did not receive craniospinal radiotherapy (88). These findings are 
consistent with those of the HIT-SKK study (89). Furthermore, an update of 
the Baby Paediatric Oncology Group I study (90) reported a 69% 5-year 
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overall survival in the same group of patients, although most patients received 
craniospinal radiotherapy (but at reduced dose of 24 Gy).  
 
These results suggest that a future strategy to improve survival of children 
with medulloblastoma should include full staging with both pre- and post-
operative MRI scanning of CNS (52;55;91) so as to offer tailored 
neurosurgical treatment with maximal  tumour cytoreduction when possible 
(55).    
 
 
 
1.7. Risk Stratification 
 
Currently, children with medulloblastoma are divided into two groups 
according to risk for recurrence, an average-risk group and a high-risk group.       
This division is based on three clinical prognostic factors: age, extent of 
tumour resection and metastatic disease (92).  
 
Children younger than 3 years of age have markedly poorer outcomes. The 
reasons for this may relate to the biology of tumours arising early in life or 
may be due to associations with known prognostic indicators (18) such as:  
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1) Younger children (less than 5 years of age) more commonly present with     
     metastatic disease (62).  
2) Oncologists may be reluctant to use conventional doses of craniospinal       
     radiotherapy (93). 
3) Young children more commonly have subtotal tumour resections (94).  
 
Residual tumour is assessed by postoperative MRI scanning within 48 to 72 
hours in order to limit the impact of postsurgical changes on MRI scan 
interpretation (52)  
 
Clinically, patients are divided into M0 and M + (M l - M4) groups for risk 
stratification. The survival disadvantage suffered by patients with metastatic 
disease is illustrated by Packer et al in a large multi-institution, single-armed 
study treating children with radiation and chemotherapy consisting of 
lomustine, cisplatin, and vincristine. Patients with M + disease at the time of 
diagnosis were shown to have a poorer 5 year progression free survival (67% 
± 15%) compared to those without metastatic disease (90%, ± 6%, p= 0.037) 
(49). Although M1 disease trends toward poorer outcomes, it has not been 
demonstrated to confer a statistically significant increased risk of treatment 
failure in the largest studies (55;95;96).  With the exception of M1 however, 
the M stage continues to be the most robust clinical prognostic indicator used 
in the current scheme of risk stratification (18).  
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Molecular biology also provides increasing insight into the genetic events that 
lead to the formation of medulloblastoma, as well as the molecular 
characteristics that predict a poor response to current therapeutic regimes. 
Discussions on this topic often contain three risk categories: high, 
intermediate and average. The intermediate risk category for example, could 
contain patients with brainstem invasion, Ml disease, age less than 3 but 
elevated TrkC, or patients with a subtotal tumour resection (18;43).  
 
In view of the absence of an accurate assessment of disease risk among 
children with medulloblastoma, Gilbertson et al (44) studied 41 primary 
medulloblastoma cases aiming to establish whether molecular abnormalities 
provide prognostic information for patients with medulloblastoma in addition 
to that afforded by clinical risk stratification. Patients’ tumour samples were 
analysed for ErbB2 receptor expression using immunohistochemistry, and for 
aberrations of chromosome 17 and amplification of the MYC oncogene using 
fluorescence in situ hybridisation (FISH). ErbB2 (also known as HER2/neu) 
abbreviates "Human Epidermal growth factor Receptor 2" and is a protein 
associated with more aggressive behavior in some breast cancers. It is a cell 
membrane surface-bound tyrosine kinase receptor and is normally involved in 
the signal transduction pathways leading to cell growth and differentiation. 
HER2 is thought to be an orphan receptor, with none of the EGF family of 
ligands is able to activate it. However, ErbB receptors dimerise on ligand 
binding, and HER2 is the preferential dimerisation partner of other members 
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of the ErbB family (97). The HER2 gene is a proto-oncogene located on the 
long arm of human chromosome 17(17q21-q22) (98).  
 
Gilbertson et al found that the ErbB2 receptor and deletion of 17p were 
detected in 80% and 49% of medulloblastomas respectively. In addition, 17p 
loss occurred either in isolation (20%), or in association with gain of 17q 
(29%), compatible with an isochromosome of 17q. Amplification of MYC 
was detected in only 2 tumours. MYC [v-myc myelocytomatosis viral 
oncogene homolog] protein is a multifunctional, nuclear phosphoprotein that 
plays a role in cell cycle progression, apoptosis and cellular transformation. It 
functions as a transcription factor that regulates transcription of specific target 
genes. Mutations, over-expression, rearrangement and translocation of MYC 
gene have been associated with a variety of hematopoietic tumors, leukemias 
and lymphomas, including Burkitt ’s lymphoma (44).  
 
Importantly, this study revealed no significant relationship between patient 
age and any molecular abnormality (44). High molecular risk patients were 
designated as those with high ErbB2 receptor expression and / or isolated 17p 
loss, while low molecular risk patients were designated as patients whose 
tumours demonstrated neither aberration.  Combined analysis of clinical and  
 
Molecular factors enabled more accurate prediction of disease risk than 
clinical factors alone, identifying a sub-population of patients with particularly 
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favourable disease outcome (44). A high ErbB2 oncogene protein expression 
was defined as presence of ErbB2 oncogene protein in ≥50% of tumour cells. 
FISH was employed to identify both the abnormalities of chromosome 17 
(imbalance on the short and long arms of chromosome 17) and MYC 
oncogene amplification in material derived from each of the tumour blocks 
employed in the analysis of ErbB2 receptor expression.  
 
More recently, Crawford et al reported a generalised algorithm for the 
stratification and treatment of medulloblastoma on the basis of age and risk 
stratification, highlighting the possibility that the presence or absence of 
biological tumour markers may alter risk stratification and future treatment 
options (Figure 2) (99). Whether these markers (genes encoding neurotrophin-
3 receptor, MYC, ErbB2, β-catenin, survivin, p53) are useful to further refine 
the clinically based stratification or obviate the need for clinical staging is 
unclear. The incorporation of these markers into the risk stratification scheme 
might also result in the definition of more exact risk subset groups (99).  
 
The most common site for a relapse is the posterior fossa in both children and 
adults (18). Late relapse is much more common in adults than in children, 
with adults displaying a median time to recurrence of 26 months and 29% of 
recurrences occurring more than 5 years after treatment (19). This is in 
contrast to the occurrence of 75% of paediatric relapses which occur within 2 
years (18;100). 
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Figure 2: Treatment scheme for medulloblastoma (99) 
Crawford et al. Lancet Neurology 2007;6: 1073-85. 
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1.8. Diagnosis 
 
 
1.8.1. Clinical presentation  
 
Children with medulloblastoma most commonly present with the classic 
symptoms of morning headache, vomiting, and lethargy, which are caused by 
a posterior fossa mass or associated hydrocephalus. Infants may have 
irritability and poor feeding. Cerebellar signs include trunkal ataxia, gait / 
limb ataxia or / and dysmetria. Brain stem invasion by the medulloblastoma 
may cause bulbar or facial nerve palsy. Sixth nerve palsy is usually as a result 
of hydrocephalus or intracranial hypertension. Impaction of the cerebellar 
tonsils into the foramen magnum may also cause torticollis (11). Affected 
children tend to maintain a fixed posture, with the head tilted and partially 
externally rotated to one side in order to reduce the pain caused from 
stretching and irritation of the dura. Passive flexion of the patient forward is 
actively resisted and results in severe pain (101). Diplopia is often present and 
is secondary to VIth cranial nerve palsy. Other symptoms include drowsiness, 
reduced appetite, loss of weight, blurred vision, macrocrania and behavioural 
changes (11;30;102). 
 
Infants less often exhibit the classic triad of symptoms because of unfused 
sutures and corresponding compensation for the elevated intracranial pressure. 
 26 
Common symptoms in infants include macrocephaly, a full anterior fontanel, 
irritability, intermittent vomiting and “sun-setting”. Papilloedema, whilst very 
common in older children, is rare in infants (11;30;102).  
 
Symptoms usually last from a few weeks up to three months (30), although 
cases of symptoms lasting for one year have been reported in the literature 
(103). A long duration of symptoms prior to diagnosis may correlate with a 
lower stage of tumour, whereas a shorter duration correlates with a higher 
stage of disease. A delay in diagnosis may be attributable to the clinicians’ 
low index of suspicion of medulloblastoma as the causative factor of non-
specific symptoms such as headache, nausea or vomiting. Patients with early 
morning headaches and vomiting may have undergone extensive 
gastrointestinal evaluation before the diagnosis of a brain tumour is finally 
made (102).  
 
 
 
1.8.2. Clinical signs 
 
The most common neurological signs at the time of presentation include: 
truncal ataxia, ataxic gait, nystagmus, cranial nerve palsy, papilloedema, 
increased head circumference, torticollis, limitation of upward gaze, and 
reduced visual acuity (11;30;102).  In addition, increasing head circumference 
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and full anterior fontanel with widely split cranial sutures may be the 
presenting signs in an infant with raised intracranial pressure due to 
hydrocephalus (104). Extension of medulloblastoma into the cerebral 
aqueduct may result in fourth cranial nerve palsy due to direct compression of 
its nucleus and decussated fibres around the periaqueductal grey matter 
(104;105). Although leptomeningeal metastases are common in children with 
medulloblastoma (30), the presence of spinal intramedullary metastasis at 
diagnosis is very rare and only three cases have been reported in the literature 
to date (106-108). 
 
 
 
1.8.3. Radiology 
 
On an unenhanced CT, medulloblastoma appears as a homogeneous 
hyperdense and well-circumscribed mass seen in the midline associated with 
the vermis (109). Vermian medulloblastomas can extend into the contiguous 
cerebellar hemisphere, brain stem, fourth ventricle and rarely through the 
aqueduct into the third ventricle (109). Medulloblastomas arising in the fourth 
ventricle can extend through the foramina of Magendie and Luschka (110). 
Uncommonly, medulloblastoma can present as a solitory cerebellopontine 
angle tumour (110). In older children and adults medulloblastomas have a 
greater predilection for the cerebellar hemispheres. Cyst formation occurs in 
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10% to 20% of paediatric cases and 59% to 82% of adult cases (111). 
Haemorrhage occurs uncommonly in paediatric medulloblastomas (111) and 
the presence of calcifications in the tumour are rare (109;111). 
 
MRI based measurements of medulloblastoma range from 2.5 cm to 5.0 cm 
(mean 4 cm) in transverse diameter on axial cuts (112). Medulloblastomas 
usually show moderate contrast uptake with a heterogeneous enhancement 
pattern (112). However, atypical features of homogenous or patchy 
enhancement may occur (113) Figure 3. On FLAIR sequences the signal is 
isointense to grey matter. This is in contrast to most other CNS tumours which 
tend to have signal that is more intense than grey matter (18).  
 
Other imaging modalities such as MRS, PET and SPECT are also used in the 
management of patients with medulloblastoma, most commonly as a clinical 
aid to distinguish tumour recurrence from post-therapy necrosis. In 
medulloblastoma, MRS typically shows raised level of choline (a marker of 
biomembranes) and decreased level of N-acetyl aspartate (a neuronal cell 
marker) and other mobile lipids (114). Taurine level (usually raised in 
astrocytomas) is occasionally seen to have a reduced peak in 
medulloblastomas on MRS (115). PET with [18]flyorodeoxyglucose (FDG) 
uptake has been used to study medulloblastoma and a positive result is found 
to be inversely related to survival (57). SPECT has also been used to study 
medulloblastoma, particularly to differentiate post-radiation changes and 
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gliosis from tumour recurrence (116). Newer neuroimaging modalities such as 
diffusion tensor imaging have been used for preoperative and postoperative 
assessment of corticospinal tract invasion in various brain tumours (117). 
Changes in relative anisotropy as assessed by diffusion tensor imaging, have 
been associated specifically with poor intellectual outcome after treatment for 
medulloblastoma (99;118). 
 
Metastatic deposits are typically identified on gadolinium TlW images as 
enhancing nodules or described as a “carpet-like” or “zuckerguss” (icing sugar) 
covering of the leptomeningeal surfaces of the brain and spinal cord. Drop 
metastases, which occur in up to 40% of patients, are most commonly seen in 
the lumbosacral and thoracic areas. However, these classic features on 
imaging as described above cannot always be distinguished from nerve root 
clumping or pial enhancement. It is therefore imperative to obtain an MRI of 
the whole spine before and after treatment for comparison (99). 
Problematically, non-enhancing metastatic disease can also be present. The 
non-enhancing metastases are often only identified on T2-weighted images as 
areas of distortion in the subarachnoid spaces or as areas of abnormal signal 
on FLAIR or diffusion images (18;119). MR is the superior study, but CT 
myelography may be more beneficial in specific cases for the detection and 
evaluation of drop metastasis on distal spinal nerve (111).  
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Early enhancement has been shown to be associated with residual tumour. 
Imaging of patients after the third postoperative day may be misleading as 
dural and operative bed enhancement may simulate metastatic subarachnoid 
and leptomeningeal metastatic disease (109). Enhancement after 3 days can be 
seen in either residual tumour or in foci of neovascularisation within the 
postoperative brain thus resulting in potential misinterpretation of CT or MR 
scans (109;120). Consequently, routine postoperative cranial imaging by MR 
should be obtained during the immediate postoperative period and certainly 
within the first 72 hours of primary medulloblastoma excision (121). Also the 
use of Surgicel for haemostasis in the tumour bed may also be misinterpreted 
as residual tumour on early post operative CT scan and should be taken into 
account when interpreting the scans (109) (Table 5).   
 
Although, Roebuck et al could not prove that surveillance imaging improves 
survival in children with medulloblastoma, they found that it is effective in 
detecting potentially curable medulloblastoma relapses and should be offered 
to all patients (122). Currently, surveillance MR imaging of children with 
medulloblastoma is used routinely. MRI scan of the head and spine are 
performed at least every 3 months for the first year after surgery and then at 
least every 6 months until three years post treatment in order to assess the 
result of treatment and to diagnose asymptomatic relapse of the disease.  
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a)  
b)  
          Figure 3. MRI Scan of medulloblastoma (a) prior to contrast,           
                          (b) after contrast enhancement 
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Table 5. Radiological profile of Medulloblastoma (111) 
 
Feature Medulloblastoma 
 
Unenhanced CT 
Enhancement 
Calcification 
Origin 
T2W 
Site 
Subarachnoid seeding 
Cyst formation 
Foraminal spread 
Haemorrhage 
 
MRS  Metabolite 
 
NAA 
Lactate 
Choline 
 
Hyperdense 
Moderate 
Uncommon (10%-21%) 
Vermis 
Intermediate intensity 
Midline 
15%-50% 
10-20% 
No 
Rare 
 
 
 
Low 
Absent 
High 
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1.9. Management  
 
At present, the treatment of patients with medulloblastoma includes surgical 
excision of the tumour followed by radiotherapy and/or chemotherapy. For 
average risk patients with medulloblastoma, the current treatment regime 
includes maximum surgical resection followed by chemotherapy and whole 
neuroaxis radiotherapy (123). Recently in the USA and Europe, the standard 
neuroaxis radiation dose has been reduced from 36.0Gy to 23.4 Gy in an 
attempt to reduce the neurological toxic side effects which are still present, 
especially in children younger than 8 years of age (124). 
 
 
1.9.1. Surgery  
 
Surgical treatment for medulloblastoma has improved dramatically over the 
past thirty years. This is primarily related to fundamental innovations in 
surgery and technology including the use of diathermy and microscope, new 
surgical instruments and the CUSA device in conjunction with significant 
improvements in general anaesthesia and postoperative care.  
 
The diagnosis of medulloblastoma is usually strongly suggested by the 
preoperative imaging studies. The T1W contrast-enhanced cranial MRI is 
carefully examined for evidence of nodular tumour deposits. An MRI 
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examination of the complete spine is obtained if the clinical condition of the 
child permits. An uncooperative child should not be subjected to deep 
sedation to obtain a detailed spinal study preoperatively since this may mask 
any deterioration in the neurologic condition and precipitate hypoventilation 
(125).  
 
In the stable patient a preoperative MRI of the spine is desirable as it 
decreases the risk of obtaining false positive results for metastases created by 
the presence of blood in the thecal sac in the immediate postoperative period. 
In addition, prior knowledge of disseminated disease should restrain the 
surgeon from removing small tumours from critical locations which is 
associated with high risk of significant neurological complications (125). 
 
 
 
1.9.1.1. Surgical complications 
 
At the beginning of the last century the reported mortality rate following 
surgery for cerebellar tumours was 42% (104;125;126). Since then, the 
associated mortality of the surgical resection of medulloblastoma has steadily 
decreased. Cushing (127) in 1932 and Bailey (128) in 1939 (as stated by 
Sutton et al (125)) reported a mortality rate of 25.2% and 15.5%, respectively. 
Thirty eight years after Bailey’s report, Bloom described an operative 
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mortality rate of 10% (100). Currently, the mortality rate ranges from 1% - 
5% (27) ,(104;125). 
 
The most common postoperative complications following posterior fossa 
surgery for the resection of medulloblastomas include haematoma, infection / 
meningitis, aseptic meningitis, hydrocephalus, pseudomeningocele, CSF leak, 
cerebellar mutism, cranial nerve palsy, and hemiparesis (104;129-132). Spinal 
deformity occurs in 5% of cases after a posterior fossa tumour resection (133). 
It is typically seen within a year of surgery and is predisposed by laminectomy 
of C2 or lower, local wound complications and possibly postoperative neck 
weakness (133). 
 
Brain stem damage may result in the need for nutritional and respiratory 
support such as gastrostomy, tracheostomy, or prolonged ventilatory support. 
“Pseudobulbar palsy” syndrome may occur approximately 72 hours following 
surgery for midline posterior fossa tumours (125;134). It tends to resolve over 
weeks and months and is attributed to retraction-induced oedema of the 
cerebellar peduncles, upper pons and midbrain (125;134).  
 
Cerebellar mutism is a well recognised complication following posterior fossa 
surgery for cerebellar tumours (135-138). The reported incidence rate in 
paediatric medulloblastoma patients varies widely between different studies 
(131;139-142). More than 200 cases have been reported in the literature 
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(136;140;142). It usually develops during the first 3-4 postoperative days and 
may persist for several months (38;129;131;140). The deficit usually recovers 
over period of weeks to 6 months (125) but some patients may experience a 
permanent deficit. 
 
Neuropsychological consequences of cerebellar tumour resection include 
expressive language deficits (37%), visual-spatial deficits (37%), both 
expressive language and visual-spatial deficits (16%) and fine motor 
coordination impairment (74%) (143).   
 
 
 
1.9.2. Radiotherapy 
 
The prognosis of patients with medulloblastoma has changed markedly since 
the introduction of postoperative irradiation of the whole neuroaxis; 
improving survival rates to 54% (144). Furthermore, the combination of 
surgery with radiotherapy and/or chemotherapy has improved the prognosis of 
children with medulloblastoma (145).  
 
Until recently the therapeutic approach for standard risk medulloblastoma has 
consisted of complete or near complete surgical resection followed by post-
operative craniospinal radiotherapy. The conventional doses of radiotherapy 
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are around 36 Gy to the craniospinal axis together with a boost of 18 to 20 Gy 
to the posterior fossa (total dose of 54 to 56 Gy) (146). In addition, 
conventional fractionation in radiotherapy has evolved empirically and 
generally involves giving one fraction per day, five days per week Monday to 
Friday. In paediatric radiotherapy practice, the daily dose per fraction is 
generally between 1.5 and. 2.0 Gy. In selecting the total dose of radiotherapy 
to be delivered to a tumour, the aim is to achieve the maximum tumour 
control with acceptable long-term morbidity. Exceeding the CNS tissue 
tolerance dose carries an increased risk of severe late morbidity including 
radiation necrosis (147). This limits the dose of radiotherapy that can be 
delivered for CNS tumours.  
 
Hyperfractionated radiotherapy involves giving a smaller dose per fraction, 
with radiotherapy fractions administered at least twice each day. The aim of 
hyperfractionation is to improve the therapeutic ratio, either by enhancing the 
anti-tumour effect without an increase in late side effects, or by maintaining 
the same level of anti-tumour effect and reducing late morbidity. In order to 
maintain an iso-effect in the tissues, the total dose has to be increased due to 
the sparing effect of the smaller fractions (146). In the past hyperfractionated 
radiation has not been shown to hold any benefit over conventionally 
fractionated radiation when used alone (148) or in conjunction with 
chemotherapy (18;149). More recently (2003) HIT-SIOP PNET 4 (146), a 
prospective randomised controlled trial of hyperfractionated versus 
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conventionally fractionated radiotherapy in standard risk medulloblastoma 
was started in order to compare the event free survival rate for children and 
adolescents with standard risk medulloblastoma (Table 6). This trial has now 
closed, having recruited the required number of patients and the data is being 
analysed. 
 
Intensity-modulated radiation therapy (IMRT) is a modern conformal 
technique that employs fused digital imaging, multiple beam angles, varied 
exposure times and energy beams shaped by dynamic multi-leaf collimators to 
deliver radiation to a tightly defined area, with the goal of reducing normal 
tissue radiation exposure. One of the main benefits of IMRT use in 
medulloblastoma is the avoidance of cochlear irradiation, hence reducing the 
incidence  of  hearing loss (150).  
 
Radiotherapy for medulloblastoma causes severe damage to the developing 
brain. Radionecrosis, mineralizing microangiopathy and calcification of the 
brain, hypopituitarism (growth hormone, FSH, LH deficiency) 
hypothyroidism, cataracts and ototoxicity are well documented long term 
complications of radiotherapy for paediatric brain tumours (151).  Perceptual 
motor task performance was below average in more than 50% of the 
participants in the series by Johnson et al, but motor dexterity was more 
severely affected than perception. Also, the majority of the participants 
developed learning difficulties and had delays in both physical growth and 
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development (152). Grill et al reported that there is a significant correlation 
between the full-scale IQ score and the craniospinal radiation dose, with mean 
FSIQ scores at 84.5 (SD= 14.0), 76.9 (SD= 16.6), and 63.7 (SD= 15.4) for 0 
Gy, 25 Gy, and 35 Gy of craniospinal radiation respectively. A marked drop 
in verbal comprehension scores was noted in children who had received the 
higher dose. Subsequently, Grill et al supported the rationale for decelerating 
the dose escalation of craniospinal radiation doses and volumes in standard-
risk posterior fossa tumours (153).  
In the CCG 9892 study, the neuropsychological effect of 23.4 Gy craniospinal 
radiation was reported to be a decline of 4.3 FSIQ points per year. Females 
were more subject to verbal IQ decline than males, and young children (< 7 
years of age) were more adversely affected than older children, with a 
significant decline in non verbal IQ (124). 
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     Table 6. The doses of radiotherapy for each arm in HIT-SIOP PNET 4 
(146) 
 
 
HFRT 
(experimental arm) 
 
Conventionally fractionated 
radiotherapy  (standard arm)  
 
Craniospinal axis:  
36 Gy in 36 twice daily fractions of 1 Gy  
 
Post fossa:  
60 Gy in 60 twice daily fractions of 1 Gy  
 
Tumour bed:  
68 Gy in 68 twice daily fractions of 1 Gy  
 
 
Craniospinal axis: 
 23.4 Gy in13 daily fractions of 1.8 Gy  
 
Post fossa:  
54 Gy in 31 fractions of 1.8 Gy  
 
 
 
 
 
 
 41 
1.9.3. Chemotherapy  
The use of chemotherapy was a major advance in the treatment of 
medulloblastoma (72). In the 1980s, the debilitating cognitive and 
endocrinological sequelae of craniospinal radiotherapy in addition to the poor 
survival rates for children with postoperative residual tumours led to 
successive randomized co-operative trials by the International Society of 
Paediatric Oncology (50), the Children’s Cancer Group (CCG 942) (48) , and 
the Paediatric Oncology Group (POG 7909) (154) which  introduced 
chemotherapy to improve survival, and later, reduce radiation dosage. At first, 
an increase in overall survival from chemotherapy was not apparent for all 
children, but only those who had bulky residual tumour or metastatic disease. 
Subsequently in the 1990s, the single-arm study CCG 9892 was performed 
and used 23.4Gy craniospinal irradiation rather than the standard 36 Gy, 
followed by eight courses of lomustine (CCNU), cisplatin and vincristine for 
children aged 3 to 10 years without residual tumour or metastases. This study 
attained a remarkable 5 year event-free survival (EFS) of 78% of children 
(155).  
 
In both CCG 921 and the German trial HIT’91, overall survival was not 
significantly different in children who were staged as having no metastasis or 
microscopic metastasis (55;96). Children younger than 3 years are always 
considered to be at high-risk because of their well established higher rates of 
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recurrence in this group of patients (78). Brain stem invasion (described as 
Chang stage T3b) was previously considered to be a high-risk indicator is 
thought now not to affect prognosis (55).  
 
The SIOP / UKCCSG PNET-3 Study is the first large multicenter randomized 
study which demonstrated improved EFS for pre-radiotherapy chemotherapy 
compared with RT alone in patients with non metastatic medulloblastoma 
(Change stage M0-1). Chemotherapy regime comprised of vincristine 1.5 
mg/m² weekly for 10 weeks; four cycles of etoposide 100 mg/m² daily for 3 
days on weeks 1, 4, 7 and 10; carboplatin 500 mg/m² daily for 2 days on 
weeks 1 and 7, and cyclophosphamide 1.5 g/m² on weeks 4 and 10. This study 
included patients aged 3 to 16 years inclusive. They were randomly assigned 
to receive 35Gy craniospinal radiotherapy in 21 fractions, followed by a 
posterior fossa boost of 20 Gy in 12 fractions or chemotherapy, followed by 
the radiotherapy.  
 
It recruited 217 patients randomly assigned to treatment. 179 (82.5%) patients 
were eligible for analysis [chemotherapy and radiotherapy, 90 (50.3%) 
patients; radiotherapy alone, 89 (49.7%) patients]. The median age was 7.67 
years and the median follow-up was 5.40 years. Overall survival at 3 and 5 
years was 79.5% and 70.7% respectively. EFS at 3 and 5 years was 71.6% and 
67.0% respectively. EFS was significantly better for the chemotherapy and 
radiotherapy group (p= 0.0366) as demonstrated by an EFS of 78.5% at 3 
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years and 74.2% at 5 years compared with 64.8% at 3 years and 59.8% at 5 
years for radiotherapy alone group. However, there was no statistically 
significant difference in 3 year and 5 year overall survival between the two 
groups (p= 0.0928). Multivariate analysis identified use of chemotherapy (p= 
0.0248) and time to complete radiotherapy (p= 0.01) as having a significant 
effect on EFS (121).  
 
Overall survival and EFS were significantly better for patients completing 
radiotherapy within 50 days compared with those requiring >50 days to 
complete radiotherapy (3-year overall survival rate of 84.1% vs. 70.9%, p= 
0.0356, 3-year EFS rate of 78.5% vs. 53.7%, p= 0.0092). Multivariate analysis 
identified the use of chemotherapy (p= 0.0248) and radiotherapy duration (p= 
0.01) as predictors of better EFS. Posterior fossa recurrence occurred in 11 
(34.4%) of 32 with a posterior targeting deviation compared with 13 (16.3%) 
out of 80 without (p= 0.043). The results of this study have confirmed the 
importance of the duration of radiotherapy treatment for children with 
medulloblastoma. Attention to detail is also important when planning 
radiotherapy, as illustrated in the case of posterior field placement (156).  
 
In the same study (SIOP / UKCCSG PNET-3 Study) but looking at Chang 
stage M2-3 stage patients with medulloblastoma who were treated with 
surgery and pre-radiotherapy chemotherapy, at a median follow-up of 7.2 
years the overall survival rates at 3 and 5 years were 50.0% and 43.9, 
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respectively, while EFS rates at 3 and 5 years were 39.7% and 34.7%, 
respectively. Univariate analysis did not demonstrate any impact of age, 
gender, M stage, extent of resection, radiotherapy duration or metastatic boost. 
For patients who commenced radiotherapy within 110 days of surgery, EFS 
was significantly (p= 0.04) worse than for those who commenced 
radiotherapy later than this. Chemotherapy was not shown to improve the 
outcome for stage M2 - M3 patients when compared with earlier multi-
institutional series (157).  
 
The SFOP study on young children with medulloblastoma recruited 79 
children aged younger than 5 years who had had surgical resection of 
medulloblastoma. Patients were treated with combination chemotherapy 
which did not include methotrexate, for more than 16 months irrespective of 
the extent of disease. Salvage therapy (including radiotherapy) was indicated 
only for disease progression or relapse during or after the end of 
chemotherapy. A second operation was considered in patients with local 
relapse or progression. In this study, the 5-year overall survival was 73% in 
the R0M0 (no residual disease, no metastasis) group, 41% in the R1M0 
(radiological residual disease alone) group, and 13% in the RXM+ (presence 
of metastasis) group. It was reported that conventional chemotherapy alone 
can be used to cure children with non-metastatic medulloblastoma who have 
gross total resection confirmed by early radiological assessment, but is not 
sufficient for treatment of those with metastatic or incompletely resected 
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medulloblastoma. Salvage treatment followed by posterior fossa radiotherapy 
can effectively treat local relapses or progression (88). 
 
 
1.9.3.1 High-Risk Disease  
 
When dealing with patients with high risk disease, current clinical trials 
employing radiation therapy include the use of radiosensitizing chemotherapy 
or post-radiotherapy high dose chemotherapy utilizing peripheral blood stem 
cells rescue (PBSC) in patients greater than 3 years of age. The COG 99701 
study uses carboplatin and vincristine concurrent with irradiation followed by 
a randomization between cyclophosphamide and vincristine or 
cyclophosphamide, vincristine and cisplatin. Post-irradiation chemotherapy 
has been demonstrated to be feasible with a regime using pre-irradiation 
topotecan followed by PBSC harvest, radiation therapy and four consolidation 
courses of vincristine, cisplatin and cyclophosphamide supported by PBSC 
rescue (158). The COG 99702 protocol uses vincristine concurrent with 
radiation followed by three cycles of high-dose chemotherapy (two cycles of 
carboplatin and thiotepa and one of carboplatin, cyclophosphamide and 
vincristine) supported by PBSC rescue (18).  
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In children less than 3 years of age, chemotherapy has been used in an attempt 
to delay or eliminate the need for radiation because the use of radiotherapy is 
contraindicated owing to its severe long-term neurocognitive sequelae. 
 
In 1986, the POG began a study for children under 36 months of age with 
malignant brain tumours. These children were treated postoperatively with 
combinations of two 28-day cycles of cyclophosphamide / vincristine 
followed by one 28-day cycle of cisplatin / etoposide. This sequence was 
repeated until the disease regressed or for 1 or 2 years depending on the age at 
diagnosis (roughly until the age of 3 years). Following this, patients received 
radiation therapy. The response rates were highest among patients with 
medulloblastomas, malignant gliomas and ependymomas. The progression-
free survival rate was 41% at one year for children who were 24 to 36 months 
old at diagnosis and 39% at two years for those under 24 months of age at 
diagnosis. Multivariate analysis identified embryonal tumours as a significant 
adverse prognostic feature and complete resection as a favourable feature. 
Complete responses to chemotherapy were associated with a progression-free 
survival rate approaching that achieved with gross total resection (94).  
 
The CCG trial used an eight-drug chemotherapeutic regime including 
vincristine, carmustine, procarbazine, hydroxyurea, cisplatin, cytarabine, 
prednisone and cyclophosphamide for patients less than 3 years of age 
following surgery and postoperative staging, 56% of whom had 
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medulloblastoma. Objective tumour response was noted in 28% of all patients 
following two cycles of chemotherapy. The 3-year PFS rate for 
medulloblastoma was 22% ± 6% (159). 
 
Rutkowski et al found that postoperative chemotherapy alone is a promising 
treatment for medulloblastoma in young children without metastases (89). 
They conducted a trial using intensive postoperative chemotherapy alone. 
Forty-three children received three cycles of intravenous chemotherapy 
(cyclophosphamide, vincristine, methotrexate, carboplatin, and etoposide) and 
intraventricular methotrexate postoperatively. The five-year progression-free 
and overall survival rates (+/-SE) in children who had complete resection (17 
patients), residual tumour (14), and macroscopic metastases (12), were 82% 
+/-9% and 93%+/-6%, 50% +/-13% and 56% +/-14%, and 33% +/-14% and 
38% +/-15%, respectively. The five-year progression-free and overall survival 
rates (+/-SE) in 31 patients without macroscopic metastases were 68% +/-8% 
and 77% +/-8%, respectively. They found that desmoplastic histology, 
metastatic disease and age younger than two years were independent 
prognostic factors for tumour relapse and overall survival. Asymptomatic 
leukoencephalopathy was detected by MRI in 19 (82.6%) out of 23 children. 
After treatment, the mean IQ of these children was significantly lower than 
that of healthy controls within the same age group but higher than that of 
patients in a previous trial who had received radiotherapy (89). 
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A SFOP trial treated relapsed medulloblastoma patients who were less than 3 
years of age and who had not received previous radiation with a conditioning 
regime of busulfan and thiotepa followed by autologous bone marrow 
transplantation. After recovery, patients with focal disease received local 
radiotherapy to the posterior fossa. A response rate of 75% was noted in 
patients with assessable disease. EFS rate was 50% at a median follow-up of 
31 months (160).  
 
1.9.3.2. Relapsed Disease 
 
Relapsed medulloblastoma remains very difficult to treat despite its relative 
chemosensitivity. Although responses have been noted with multiple single 
agents including cyclophosphamide, cisplatin, methotrexate, carboplatin and 
oral etoposide, tumour recurrence is inevitable (18).  
 
Modest success however has been achieved with high-dose regimens that are 
supported by PBSC rescue. A CCG pilot study using a single cycle of high-
dose carboplatin and thiotepa followed by PBSC infusion, demonstrated 
objective responses in one third of patients with PNET / MB but also a high 
incidence of complications due to drug toxicity and a mortality rate of 16%. It 
was also noted that patients with minimal residual disease experienced the 
greatest survival benefit (P < 0.0005) (161).  In a follow-up CCG study, 23 
patients with relapsed medulloblastoma received a high-dose chemotherapy 
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regimen consisting of carboplatin, thiotepa and etoposide with PBSC rescue 
resulting in a 3-year event free survival of 34% and a 3-year overall survival 
of 46% (162). 
 
 
 1.9.4. Genetic treatment 
 
Molecular genetics is providing insight into the mechanisms whereby tumour 
cells achieve and maintain escape from normal growth controls, gain 
metastatic potential and affect drug resistance. Therapeutic targets are being 
exploited with antibody-conjugated agents as well as small molecule 
inhibitors in the setting of phase I/II clinical trials. Among the agents being 
evaluated for medulloblastoma therapy is Erlotinib, an inhibitor of the ErbB2 
receptor (163). SCH66336 is an oral farnesyl transferase inhibitor that blocks 
the activity of the proliferative Ras pathway (164). Lastly, gefitinib inhibits 
the activity of the PDGF receptor, which induces proliferation through the 
Ras/MAP kinase pathway. While efficacy data is not available, phase I trials 
are demonstrating minimal drug toxicity in the patients (18). Rood et al 
reported that future use of these agents is likely to include combinations of 
drugs to block the pathways at multiple signalling levels or to inhibit different 
pathways. These agents used in combination with conventional cytotoxic 
chemotherapy is another attractive option to enhance therapeutic efficacy with 
minimal escalation of toxicity (18). 
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1.10. Justification 
 
In order to evaluate the response of medulloblastoma to treatment and to 
improve the patient’s outcome, a series of various staging systems have been 
reported in the literature and used in clinical practice over the past few 
decades (20;41;44;55;58;63;87;99;165-167). Various types of data 
(demographic, operative, histopathological and genetic) have been used in 
various combinations in these staging systems, suggesting that currently there 
is no perfect staging system for medulloblastoma. Consequently there is a 
need for the development of a more accurate staging system, which will help 
to optimise the decision making process and improve outcomes.  
 
In Chang’s staging system (20) the limit of 3 cm in tumour diameter was used 
in order to distinguish the different T stages (T1 from T2 stage), but the 
rationale for the selection of that figure as a cut off remains unclear. However, 
it was demonstrated that patients with early lesions (T1 and T2) responded to 
radiotherapy much more favourably compared to late lesions, T3b and T4. This 
highlights the significance of the size of the primary medulloblastoma in 
patient outcome (20). The above conclusion was re-confirmed in a further 
study by Harisiadis et al nine years later (63). 
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Similarly, the MAPS staging system (41) when measuring residual tumour, 
uses a figure of 1.5 cm to differentiate between stage S1 and S2. The rational 
of this is again unclear. 
 
Chang et al had stated that attempts at radical surgical resection of 
medulloblastoma should be avoided as it is a radiosensitive and radiocurable 
tumour (20). More recently, Kombogiorgas et al also reported a series of 
children with medulloblastoma from Birmingham Children’s Hospital with 
similar 5-year survival rates in patients with total and sub-total excision of 
medulloblastoma at 61.1% and 61.8% respectively (103).  
 
The absence of significant differences in survival between patients with total 
or sub-total excision of medulloblastoma strengthens the view that total 
excision of medulloblastoma can be avoided when the risk for potential intra-
operative damage and subsequent neurological deficits is high. In current 
neurosurgical practice, the goal of surgical resection is complete removal of 
tumour whenever possible, accepting a certain degree of postoperative 
morbidity (18;89). Operative attempts to excise medulloblastoma from the 
brain stem is associated with an increased risk of neurological deficits of a 
temporary or sometimes permanent nature, even when the surgeon is aided by 
modern adjuncts such as evoked potential monitoring (125). Postoperative 
complications and neurological deficits resulting from surgery not only impact 
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upon quality of life but may also contribute to the delay in commencing 
necessary adjuvant therapy.  
 
Another problem with the current staging systems of patients with 
medulloblastoma is lack of universal consensus regarding the classification of 
the degree of tumour excision (30;48;48;52;89;121;125;168). Sutton et al 
defined total resection in the strictest sense as the absence of visible tumour in 
the operative bed as well as the absence of tumour on postoperative enhanced 
MRI scans. A resection is deemed subtotal if the surgeon felt that a small 
amount of tumour had been left insitu or if the postoperative scan shows areas 
of enhancing tissue in the tumour bed (125). Albright et al defined the degree 
of tumour excision (Table 4) as total when no visible tumour is evident at the 
completion of resection; near-total when more than 90% resection of the 
primary tumour was achieved but visible tumour remains and subtotal when 
51-90% resection has been achieved (52). In other series the degree of tumour 
excision is defined in broader terms such as subtotal excision if more than 
50% of the primary tumour has not been resected (48)  or as complete and 
incomplete resection (89). Over the last 20 years, various series have reported 
less than total/subtotal excision in 24%-80% of patients operated for 
medulloblastoma (47;48;52;88;96;121;169), which makes the comparison of 
patients’ outcomes between the different series inaccurate.  
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It has become clear that post-operative imaging studies is superior to the 
subjective impression of the surgeon in estimating the extent of resection of 
posterior fossa tumours (125). The current method of radiological estimation 
of postoperative residual medulloblastoma also does not provide information 
about the total volume of residual tumour (52;89;157), as it measures only the 
cross section of the largest demonstrated part of residual tumour in a single 
axial MR slice (52;89). Subsequently, further smaller residuums which are 
demonstrated in different slices of MR scan series are not included in the 
estimation of the size of the total residual tumour.  
 
Since the 1980s, with the introduction of the MAPS staging system, the 
postoperative residual tumour volume has been reported in many studies as an 
independent prognostic factor in the outcome of patients with 
medulloblastoma (44;46;50;52-55). In all of these studies the assessment of 
tumour size was done by measuring the maximum diameter of tumour on 
axial views on CT or MR scans resulting in an underestimation of the actual 
size of the residual medulloblastoma.  
 
The need for a new study to determine a more accurate method of assessment 
of residual tumour is required. In this study a MR image analysis method was 
used to measure the volume of primary and residual medulloblastoma on pre- 
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and immediate postoperative MR scans respectively, in order to examine the 
relationship between the degree of surgical excision and outcome.  
 
A knowledge of the maximum volume of residual tumour that may be left 
unresected at the tumour bed without significant detriment to outcome 
provides neurosurgeons with a clearer and more practical view of the 
operative goal. It may also direct the potential need for “second look” 
operations in the event of large residual tumour volume being found on the 
immediate postoperative MRI scan. 
 
 
 
1.11. Aim of the study 
 
This study aims to re-evaluate the role of residual disease following primary 
operative treatment for medulloblastoma as a risk factor for patients’ outcome 
by evaluating the absolute volume of primary and residual tumour and 
residuum tumour ration. This avoids the described flaws of previous studies as 
it does not assess only a fraction of residual medulloblastoma on immediate 
postoperative MR scan but its total volume. It is a pilot study which will 
estimate the required prerequisites for a further larger study of the role of 
volumetrically assessed residual tumour in clinical outcome of children with 
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medulloblastoma. The need for this pilot study arises from the absence of any 
relevant published study or data. 
 
In this study, volumetric measurement of the tumour residuum was correlated 
to survival rates. Potentially, the results could also affect the decision to re-
operate on some patients with residual tumour.  
Currently, a significant residuum is arbitrarily defined as that with a maximum 
cross-sectional area of greater than 1.5 cm² (55) on the immediate 
postoperative MR scan. These patients are classified as high risk requiring 
more aggressive adjuvant treatment (18;43;99).  
The CCG 921 Randomized Phase III Study (55) was the trial which 
introduced the value of 1.5 cm² of residual tumour on cross section of 
immediate postoperative CT or MR scan as a limit for the risk stratification of 
patients. Based on that study, patients with residual tumour of ≤1.5 cm² on 
immediate postoperative MR or CT scan fall into the low risk category for 
tumour recurrence and those with residual tumour of > 1.5 cm² are considered 
to be high risk patients for tumour recurrence (55).  
 
In clinical practice, neurosurgeons routinely use a percentage in order to 
express the extent of brain tumour resection. In this study, the value of 15% 
was used as a cut off point in order to compare survival rates. Patients with a 
postoperative residual tumour volume of less or equal to 15% and more than 
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15% of primary medulloblastoma volume were considered low and high risk 
respectively. The consensus view of experienced paediatric neurosurgeons 
was that the final 15% of medulloblastoma was the most difficult to remove 
hence the figure selected. This study aimed to test if a greater than 15% 
residual tumour volume was an adverse prognostic feature. The study was 
designed to test the null hypothesis; that there was no difference in outcome 
between these two groups. Patients were divided into two arms:  
 
1. The first arm included children with residual tumour of ≤15% of primary 
medulloblastoma volume. 
2. The second arm included children with residual tumour >15% of primary 
medulloblastoma volume.   
 
Estimation of achieved tumour resection as a percentage of the primary 
tumour volume is difficult and depends on knowing the original tumour 
volume. The volume of large residual ratio (percentage) of small primary 
tumours might be less than the volume of small ratio (percentage) of large 
primary tumours. In order to solve the above problem, the absolute values of 
residual tumour volume were measured in cm³ and were used to find a 
correlation between residuum tumour volume and outcome.  
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Chapter 2 
 
2.1. Patient population 
 
The patients participating in this study were recruited from Birmingham 
Children’s Hospital, Birmingham, U.K. and Hôspitale Necker-Enfants 
Malades and Institute of Gustave-Roussy, Paris, France.  
 
Each child treated at Birmingham Children’s Hospital with a brain tumour is 
registered routinely with the Cancer Registry of Birmingham Children’s 
Hospital and the UKCCSG Registry upon admission and diagnosis. Patients 
were recruited from the computer database of the Cancer Registry at 
Birmingham Children’s Hospital and actively followed up in the Oncology 
and Neurosurgery Clinics.  
 
Each child treated at Hôspital Necker-Enfants Malades with a brain tumour is 
registered routinely with the SFOP Registry upon admission and diagnosis. 
Patients for this study were recruited from the computer database of the 
Institute of Gustave-Roussy Registry and actively followed up in Oncology 
and Neurosurgery Clinics.  
 
All children treated at Birmingham Children’s Hospital between 1999 and 
2006, and Hôspital Necker-Enfants Malades and Institute of Gustave-Roussy 
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in Paris between 2002 and 2005 for medulloblastoma have been followed up 
until the time of writing or death. All significant clinical events have been 
recorded.  
 
The study series has 37 children in total.  25 of children were treated at 
Birmingham Children’s Hospital between 1999 and 2006 and 12 children 
were treated in Hôspital Necker-Enfants Malades and Institute Gustave-
Roussy between 2002 and 2005.  
 
The end point in the study is the date of most recent follow up for patients 
who were alive at the time the thesis is written or the date of death for patients 
who died. 25 children were eligible to be studied from a series of 42 children 
who received operative and oncologic treatment at Birmingham Children’s 
Hospital between 1999 and 2006. 12 children were eligible to be studied from 
a series of 53 children who received operative treatment at Hôspital Necker-
Enfants Malades and oncological treatment at the Institute Gustave-Roussy 
between 2002 and 2005.  
 
The reasons of exclusion of patients from the study were as follow: 
 
1. Absence of available preoperative or immediate postoperative MRI scans 
data in DICOM form (Chart 1).  
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It was impossible to retrieve either the preoperative or postoperative MR 
scans in DICOM form in 15 patients from BCH and 37 patients from Necker-
IGR Hospitals (52 cases in total) because of: 
a) Loss of some optic discs that the MR scans were stored in DICOM form 
b) Incompatibility of the old optic discs of Necker Hospital with its new MR      
scanner. Also, in some cases the first postoperative MR scan was performed 
after the commencement of adjuvant treatment. Subsequently those cases were 
excluded from the study as they did not fulfil the selection criteria of the study.  
 
2. Absence of clinical information regarding the treatment protocol of the 
patients (unobtainable medical notes in 6 cases). 
 
 
 
2.2. Ethical approval 
 
Application for ethical approval for the current research project was submitted 
to the South Birmingham Local Research Ethics Committee. The application 
form set included copies of: 
 
1. Parent / Child consent form.  
2. Family Doctor Information Sheet. 
3. Patient / Family Information Sheet. 
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4. Thesis-Research Project Outline. 
5. Study Participant Invitation Letter. 
 
Ethical approval was obtained from the South Birmingham Local Research 
Ethics Committee permitting completion of the current research project. 
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 Chart 1. Algorithm of selection process of eligible patients for study  
                 based on availability of pre- and post-operative MRI brain  
                 in DICOM form 
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2.3. Patient selection criteria 
 
 
2.3.1. Inclusion Criteria 
 
The inclusion criteria were: 
1. Patients with a histologically confirmed diagnosis of medulloblastoma (29). 
 
2. Patients aged less than 16 year of age at the time of histological diagnosis. 
 
3. A complete set of MR brain examinations before and after primary 
posterior fossa surgery available in DICOM form (minimum modalities of 
examination: Axial T1W with contrast enhancement and Axial T2W 
sequences).   
 
 
2.3.2. Exclusion criteria 
 
The exclusion criteria were: 
1. Patients with no immediate postoperative MR brain. 
 
2. Unavailability of a complete set of MRI of the brain in DICOM form  
    (Chart 1). 
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3. Patients older than 16 years of age at the time of histological diagnosis. 
 
4. Patients previously treated for medulloblastoma. 
 
 
 
2.4. Methodology  
  
The study required an accurate estimation of medulloblastoma volume, which 
was achieved by using image analysis from the neuroradiological 
examinations for every patient. Calculation of medulloblastoma volumes was 
achieved after image analysis of preoperative and immediate postoperative 
MR scans of each patient by using segmentation techniques. Preoperative and 
immediate postoperative medulloblastoma volumes were then plotted against 
age for analysis. This created a scatter plot demonstrating the pre and post 
primary surgical excision volumes of each patient with medulloblastoma. 
Statistical calculations were then performed to correlate the extent of tumour 
excision to outcome. The categorical data (alive-dead) of two patient 
groups/arms (i.e. residual tumour ratio more or equal-less than a specific limit) 
was calculated using chi-squared test and Fisher’s exact test. 5-year survival 
data was analysed using the Kaplan-Meier method. This method was chosen 
over logistic regression or comparison of the mean time to reaching the 
endpoint in patients with and without a new treatment to avoid problems of 
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censored data within the latter. The log-rank test was used to address the null 
hypothesis which states that there are no differences in survival times in the 
groups being studied, and compares events occurring at all time points on the 
survival curve. However, as the log-rank test is unable to assess the roles of 
independent factors against the endpoint, a regression model (i.e. cox 
regression analysis) was used to quantify the relationships between one or 
more potential significant prognostic factors of patients’ outcome (i.e. gender, 
age, presence of metastasis at the time of diagnosis). Finally, a Receiver 
Operating Characteristic (ROC) curve was used to assist in the selection of the 
optimal residual ratio and residual volume cut-off value.  
 
The minimum required number of patients for the study was calculated by 
power analysis. The research study outline was submitted to The Division of 
Neuroscience of Medical School of the University of Birmingham and was 
externally peer-reviewed and deemed suitable for the purpose of an MPhil 
study.  
 
 
2.5. Image analysis technique and tumour volume measurement 
 
Segmentation technique is the process whereby a composite CT or MR image 
is broken down to several simple images which can be easily manipulated and 
reconstructed in three dimensions. In this study, every MR image is comprised 
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of a matrix of pixels which is usually square; for example 256 x 256.  Each of 
these pixels has a unique grey value within a predetermined range.  Because 
this range is much wider for MR images, different brain structures are imaged 
as subtle differences of grey signal. Segmentation allows grouping of pixels 
into regions, hence defining the boundaries of different structures (170).  
 
The segmentation technique has been used in many other neurosurgical 
studies in the past (114;171-178), including measurements of tumour volume 
and its response to therapy (170;179). Recently, Mariani et al studied the 
impact of tumour volume and surgical resection on the long-term outcome of 
patients with supratentorial, diffuse, WHO grade II astrocytomas and oligo-
astrocytomas by using image analysis (180). Also, Xie et al reported the 
development of a semi-automated MR image analysis method for brain 
tumours, which can be used as a staging procedure and a method of evaluating 
tumour response to treatment in clinical practice (181). 
 
There are three methods of segmentation techniques; manual (supervised) 
(182;183), semi-automatic and automatic (the latter two methods are 
unsupervised) (170). The semi-automatic method requires operator 
intervention in order to complete the process. The automatic method is 
operator independent (170). In this study, the semi-automatic method was 
used to outline the tumour edges and distinguish it from the adjacent 
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structures such as surrounding oedema of the cerebral tissue, scar tissue or 
blood clots.  
 
Variability in serial volume measurements and inconsistencies between 
observers have been reported in the literature in studies involving tumour 
volume measurement methods employed to assess tumour response to 
treatment or to plan treatment (170;184;185).  The manual method of tumour 
volume measurement is potentially subjective and prone to large variations in 
intra- and inter-operator performance. Joe et al compared the manual and 
semi-automatic methods of brain tumour volume measurement (186). They 
reported that the semi-automated computer method of measuring tumour 
volume has similar reliability compared with the manual trace method but is 
faster. It is regarded as an alternative method to manual tracing for measuring 
serial tumour volumes in patients with high grade brain neoplasms (186).   
 
Shan et al reported the development of a robust and accurate automated 
method for identification of the cerebellum on MR images of patients with 
medulloblastoma. This method may be applied to investigations that require 
segmentation and quantitative measurement of MR images of the cerebellum 
(187). However, the manual segmentation technique was employed as:  
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1. It can differentiate and trace boundaries of tumour from oedema or residual 
tumour from haemorrhage with greater accuracy (181;188). The assistance of 
T2W MR images was used in difficult cases. 
 
2. The segmentation technique used in this study has been previously used in 
the Informatics Laboratory at The Institute of Child’s Health in Birmingham 
in other research projects (173-178;189) and has proven to be accurate and 
reliable. This is particularly shown in a previous study measuring changes in 
intracranial volume in childhood (172). In this study, patients had ordinary 
MR sequences (5 mm slice thickness and 2 mm interval slice thickness (5/2) 
and volumetric coronal MR sequences consisting of 124 contiguous slices of 
1.5 mm thickness (1.5/0). In these patients, intracranial volume calculated by 
measuring 19 axial T2W slices (5/2) and was compared with volumes 
calculated by measuring T1W slices (1.5/0). In all cases the difference was 
less than 5% ranging from 0.06% to 4.5% (mean 2.8%) (172).  
 
The use of MR segmentation technique has been validated by the methods 
outlined below: 
1) Phantom models (object filled with known volume of water) when    
repeated measurements are performed by the same or different operators.  
 
2) Additional software in order to prevent mis-calibration of operating image 
analysis program.  
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However, the measurement of tumour volume by image analysis is limited by 
the inability to measure tumour tissue that escapes from MR discriminative 
sensitivity. In practice, MR scan does not pick up tumours with a thickness of 
less than 2 mm. 
 
The segmentation software used for this study was designed by members of 
the Department of Computer Science at the University of Birmingham (190-
194) and has been in continuous use since 1995 in numerous research projects 
(171;173-178;189;193).  It has the ability to manipulate a variety of digital 
images, including CT and MRI.  It operates on a Sun workstation (Sun 
Microsystems, California, USA) situated at the Neuroscience Informatics 
Laboratory of The Institute of Child Health at Birmingham Children’s 
Hospital and is connected via Local Area Network to the consoles of the MRI 
and CT scanners.  Thus, images can be imported to the workstation via the 
network but also from external sources such as CDs or DVDs.  Any form of 
digital imaging from any source can be used.    
 
The computer assisted image analysis was performed using the MR brain scan 
data stored in DICOM format. After importing the images to the software, 
segmentation was performed. The interface between tumour (primary or 
residual medulloblastoma) margin and the surrounding cerebellum was 
outlined in each slice of gadolinium enhanced T1W MR image of brain scan. 
For those cases in which there were difficulties in distinguishing the tumour 
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boundaries from their associated surrounding oedema T2W images were also 
reviewed. This enabled comparison with gadolinium enhanced T1W MR 
images, in order to avoid inclusion of the surrounding oedema within the 
outlined tumour perimeter. After outlining the cross section of the tumour 
(Figure 4), the system calculated the outlined area in mm² and multiplied this 
by the slice thickness to calculate the volume of each slice. The total volume 
of the primary or residual tumour was calculated by adding the volume of all 
slices.  
 
MRI scans for this study included some preoperative images with a thickness 
of 5 mm and an interval of 1.5 mm (5/1.5) between slices (MR series of 19 
slices) and in other patients with volumetric series of 108 slices (images with 
a thickness of 1.62 mm each and absence of interval gap between them: 
1.65/0). Postoperative MR scans amounted to 19 slices in all cases. The 
validation of measurement accuracy between MR scans of 19 and 108 slices 
has been completed and found to be satisfactory (172). The volume of the 
interval slice was calculated using the surface areas of the preceding slice and 
subsequent slice along with the thickness of the interval slice (1.5 mm) as 
follows:  
 
volume of interval slice = [(surface area of preceding slice + surface area of 
subsequent slice)/2] x 1.5  
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in which (surface area of preceding slice + surface area of subsequent 
slice)/2 is the mean of the two adjacent slices, which corresponds to the 
surface area of the interval slice multiplied by 1.5 (the thickness in millimetres) 
used to calculate the volume of the tumour.  
 
The medulloblastoma volume is calculated in two stages:  
 
i.   The preoperative volume (Vol. Pre), 
ii. The immediate postoperative volume (Vol. Post)  
 
The immediate post-operative MR brain scans were done within 48 to 72 
hours of primary tumour excision.  
 
The residuum ratio is calculated as follows:  
 
Residuum ratio (RR)= Postoperative Volume  / Preoperative Volume. 
 
This describes the amount of residual tumour after primary excision. 
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(a)        
                                    
(b) 
    Figure 4. Outlined boundaries of medulloblastoma (a) primary tumour,   
                     preoperatively, (b) residual tumour, postoperatively. 
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2.6. Power Analysis 
 
A power analysis was performed in order to estimate the number of patients 
required for this study. In the last 40 years, the survival rate of 
medulloblastoma has improved as a result of radical surgical excision of the 
tumour along with adjuvant treatment (radiotherapy to the craniospinal axis, 
with or without chemotherapy). However, there is considerable variation on 
the survival rates reported from various centres with reports of overall 5-year 
survival ranging from 32% to up to 83% in different studies 
(47;49;50;52;63;89;195-199). In the more recent studies the overall 5-year 
survival of children with medulloblastoma is reported as approximately 70% 
(47;52;89;195;199). 
 
The number of patients required to be recruited for the current study was 
calculated by using a software for statistical power analysis and sample size 
determination (Query Advisor®, Statistical Solutions Ltd, Cork, Ireland). The 
calculation is as follows: for maximum probability of rejecting the null 
hypothesis when it is true [Type I / alpha (α) error] with an alpha value of 0.05, 
and also the probability of not rejecting the null hypothesis when it is false 
[Type II / beta (β) error] with a beta value of 0.2 and a power of the test of 
80%, the minimum sample required for each group is 18 patients to detect a 
minimum difference of 50% in survival, with a standard deviation of 5% for 
residuum ratio. The available number of patients for each group in this study 
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therefore satisfies the minimum requirements needed.  
 
 
2.7. Statistical analysis  
 
Statistical analysis was performed using SPSS software programme [version 
16.0, SPSS Inc, USA, 2007]. Chi-square was used to identify factors of 
significance. Logistic regression analysis was used to investigate the effect on 
survival of all variables that proved significant on chi-square. Analysis of 
Variance (ANOVA) was used to compare mean values and Kaplan-Meier 
survival analysis was performed for each subgroups. Kaplan-Meier survival 
analysis was used for each individual factors and Cox-regression analysis for 
multifactorial survival analysis. Significance was set at p= 0.05.   
 
Population characteristics were studied including the following variables: age 
at diagnosis, gender, duration of symptoms, presence of metastasis or 
hydrocephalus at time of diagnosis, extent of resection, postoperative adjuvant 
therapy i.e. radiotherapy and / or chemotherapy. The follow up period was 
defined as the period from the date of diagnosis up to the date of last medical 
review of patient or the date of death of patient.  
 
In order to compare the degree of surgical excision of medulloblastoma with 
patients’ actuarial survival the following values of Residuum Ratio (RR: Vol 
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Post / Vol Pre) were used as a cut off: 15% based on the study null hypothesis. 
Also, another two cut off values were also studied, which have been used in 
clinical practice in patients’ staging process and used in published trials as:   
 
1) 10% rate from Children’s Cancer Group-921 study of the extent of 
medulloblastoma resection (52) 
 
2) 1.5 cm³ based on the Children’s Cancer Group -921 Randomised Phase III 
Study (55), as that study used the 1.5 cm² of surface area of residual tumour as 
cut off. If it is considered theoretically that the residuum has spherical shape 
then for its largest circle surface size of 1.5 cm² the corresponding sphere 
volume will be 1.38 cm³ ≈ 1.5 cm³.  
 
In addition, the overall 5-year survival and mortality rates were correlated to 
gender, age at the time of diagnosis for patients above and under 3 years and 
the preoperative tumour volume (absolute value). 
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Chapter 3 
 
3.1. Population 
 
From the study series of 37 children with medulloblastoma, there were 26 
(70%) males and 11 (30%) females (ratio of 2.3:1), Figure 5. This is in 
keeping with reports in the literature which cite a male preponderance 
demonstrated by a male to female ratio of 2:1 (11;15). The patients age at the 
time of diagnosis ranged between 7 months and 181 months (median: 67 
months, mean: 76.9 months and SD: 46.6 months). Thirty (81%) patients were 
over the age of 3 years and 7 (19%) under the age of 3 years at the time of 
diagnosis, Figure 6. The follow up period for all patients ranged from 6 
months to 117 months (mean: 45 months, SD: 31 months). The mean follow 
up time for the patients alive was 65.4 months (range: 36 - 117 months, SD: 
23.8, median: 56 months). 15 (40.5%) of 37 patients died during in follow up 
period. The mean survival time of deceased patients was 15.5 months (range: 
6 - 29 months, SD: 6.5 months, median: 14 months). The minimum follow up 
time for the patients alive was 36 months which exceeded the maximum 
survival time of deceased patients. Table 7 is a list of the all patients in this 
study demonstrating (presented with a code number: P1, P2, etc., P: studied 
patient) and incorporating the details of gender, follow up time (in months), 
and if the patients were alive or deceased at the time of latest notes review. 
Patients are listed in age order. 
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Figure 5. Gender of patients. 
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      Figure 6.  Graph of patients’ ages at the time of diagnosis. 
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Table 7.  Features of patients included in this series 
 
   M: male, F: female, m: month, F/U: follow up Y: yes, N: no, VolPre: Pre-operative tumour volume,   
   VolPost: Post operative tumour volume, RR: residuum ratio, M0: absent metastatic disease at  
   presentation, M+: present metastatic disease (M1-M4). 
Case 
no. 
Age 
(m) 
Gender 
 
F/U time 
(m) 
Death 
 
VolPre 
(cm³) 
VolPost 
(cm³) 
RR 
 
 
   Stage  
(M0/M+) 
 
P1 
 
7 
 
M 
 
14 
 
Y 24.36 0 0 
 
M+ 
P2 7 M 52 N 16.33 0 0 M0 
P3 10 M 57 N 4.47 0 0 M0 
P4 12 M 20 Y 52.85 0.64 0.01 M0 
P5 24 M 55 N 71.99 0 0 M0 
P6 29 M 29 Y 45.55 0 0 M0 
P7 34 M 13 Y 45.23 11.77 0.26 M0 
P8 37 F 49 N 36.33 0.41 0.01 M0 
P9 39 M 10 Y 17.83 0 0 M+ 
P10 40 M 14 Y 57.71 9.77 0.17 M0 
P11 41 M 9 Y 46.2 10.6 0.23 M+ 
P12 42 M 14 Y 45.44 9.64 0.21 M+ 
P13 49 F 63 N 22.04 11.47 0.52 M0 
P14 50 M 6 Y 9.47 1.3 0.14 M+ 
P15 53 F 57 N 24.31 0 0 M+ 
P16 61 M 12 Y 42.95 3.37 0.08 M+ 
P17 62 M 10 Y 24.36 0.48 0.02 M0 
P18 66 M 63 N 26.47 4.48 0.17 M0 
P19 67 M 16 Y 13.32 0 0 M+ 
P20 80 M 36 N 29.44 0.99 0.03 M+ 
P21 83 F 86 N 41.92 1.03 0.02 M0 
P22 84 F 38 N 34.51 1.41 0.04 M0 
P23 86 F 104 N 38.83 6.84 0.18 M+ 
P24 98 M 55 N 22.54 0 0 M0 
P25 101 F 25 Y 31.34 23.27 0.74 M0 
P26 103 F 114 N 24.06 8.72 0.36 M0 
P27 110 M 45 N 20.92 1.88 0.09 M0 
P28 112 M 97 N 55.6 0 0 M0 
P29 112 M 81 N 12.32 0 0 M0 
P30 125 M 117 N 16.62 0 0 M+ 
P31 132 M 17 Y 19.4 0 0 M0 
P32 132 M 55 N 30.61 0 0 M0 
P33 141 F 55 N 46.87 5.23 0.11 M0 
P34 142 F 48 N 4.53 0.65 0.14 M0 
P35 143 M 48 N 41.6 1.01 0.02 M0 
P36 152 M 63 N 50.98 5.35 0.1 M0 
P37 181 F 24 Y 34.53 1.85 0.05 M+ 
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3.2. Symptoms 
 
Information on symptoms and clinical signs was available in 94% of 37 
studied patients. Patients presented with vomiting (73%), headache (62%), 
ataxia/ataxic gait (43%), sleepiness (14%), loss of weight (14%), reduced 
appetite (11%), diplopia (11%), change of personality (8%), torticollis (5%), 
blurred vision (5%), increased head size (5%) and irritability (3%).  
 
The symptoms present prior to diagnosis lasted from 1 day to 43 weeks (mean: 
9.4 weeks, SD: 9.7). Data of duration of symptomatology were available in 33 
(89%) of 37 cases. 
 
 
 
3.3. Signs  
 
Neurological signs at time of presentation included: ataxia/ataxic gait (49%), 
papilledema (46%), cranial nerve palsy (19%), reduced visual acuity (8%), 
nystagmus (5%), increased head circumference (5%), torticollis (5%), 
limitation of upward gaze (3%) and neck stiffness (11%). One of four children 
aged less than 2 years had a tense anterior fontanel at presentation.  
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Radiologically proven hydrocephalus was found in 30 patients (81%), 24 of 
them over the age of 3 years and in 6 patients under the age of 3 years.  
 
 
 
3.4. Metastases at diagnosis 
  
A total of 12 (32%) patients had developed metastases at diagnosis. 
Radiologically proven tumour metastasis was found in 8 (22%) of 37 patients 
at the time of presentation.  Five of those patients (17%) had spinal metastases 
and three patients had cerebro-spinal metastases. The remaining 4 patients 
were found to have metastatic disease when medulloblastoma cells were 
found in the CSF when they underwent diagnostic lumbar punctures. A total 
of 11 (30%) of 37 patients underwent diagnostic lumbar puncture for staging. 
 
 
 
3.5. Surgery 
 
All 37 patients underwent surgery in the form of posterior fossa craniotomy or 
craniectomy for histological diagnosis and tumour excision.  
 
Histological diagnosis of this series is as follows: 
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33 (89%) of 37 patients had classic medulloblastoma variant, 2 (5%) patients 
had desmoplastic medulloblastoma and the other 2 (5%) had anaplastic 
medulloblastoma.  
 
Postoperative complications occurred in 11 (30%) patients. They included: 
cranial nerve palsy (16%), hemiparesis (14%), hydrocephalus (14%), 
intracranial haematoma (8%), CSF leak (8%), mutism (8%), 
pseudomeningocele (3%) and infection/meningitis (3%).  
 
 
 
3.6. Medulloblastoma volume  
 
Medulloblastoma volume was measured in all 37 patients, both preoperatively 
and in the immediate postoperative period. No patient underwent adjuvant 
therapy prior to pre- or postoperative MR scans. As such, the measurement of 
primary and residual medulloblastoma volume was not affected by any form 
of therapeutic manipulation except the primary surgical tumour excision. 
Table 7 shows the patients preoperative and postoperative tumour volume (in 
cm³) and the residuum ratio (postoperative tumour volume / preoperative 
tumour volume).  
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The mean preoperative primary medulloblastoma volume was 31.9 cm³ (range: 
4.5 cm³ - 71.9 cm³, SD: 15.9 cm³). The mean postoperative residual 
medulloblastoma volume was 3.3 cm³ (range: 0.0 cm³ - 23.3 cm³, SD: 5.1 
cm³), Table 8 and Figure 7. The mean Residuum Ratio (RR) was 0.1007 
(range: 0.0 - 0.7, SD: 0.16), Figure 8. 
 
Total primary tumour excision was successfully performed in 14 (38%) of 37 
patients as confirmed radiologically. 9 (24%) of 37 patients had residual 
medulloblastoma volume greater than 15% of the primary medulloblastoma 
volume. The remaining 14 (38%) patients in this study had residual 
medulloblastoma volume less than 15% of the primary medulloblastoma 
volume, Table 9. 
 
Three patients (P13, P25, P26) had exceptionally large residual tumour 
volume as demonstrated in Table7, Figures 7, 8 and 12. They were all females 
and had no metastatic disease at the time of diagnosis. They were operated on 
by different neurosurgeons. In particular: 
 
P13 was 49 months of age and had partial excision of medulloblastoma (RR: 
0.52, residuum volume: 11.47 cm³). She suffered a complication with 
postoperative bilateral extradural haematomas due to pin fixation of the head. 
She subsequently underwent emergency craniotomy and evacuation of the 
extradural haematomas. Postoperatively, she had severe ataxia, bulbar palsy 
 83 
and cerebellar mutism postoperatively. She received craniospinal radiotherapy 
(55Gy) and completed chemotherapy according to UKCCSG infant PNET 
Protocol. This patient was alive at 63 months from the time of diagnosis until 
the end of the study. 
 
P25 was 101 months of age and underwent partial excision of a large cell 
anaplastic medulloblastoma (RR: 0.74, residuum volume: 23.27 cm³). She 
developed postoperative hydrocephalus requiring ventriculo-peritoneal shunt 
insertion. Despite this complication she received craniospinal radiotherapy 
and chemotherapy but died 25 months after diagnosis due to relapse of her 
disease. 
 
P26 was 103 months of age and had an uncomplicated subtotal excision of 
medulloblastoma (RR: 0.36, residuum volume: 8.24 cm³). She had received 
craniospinal radiotherapy and chemotherapy according to PNET 3 protocol 
and recurrent PNET protocol respectively. This patient was alive at 114 
months from the time of diagnosis until the end of the study. 
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Table 8. Mean volume of medulloblastoma (37 cases) 
VolPre: Pre-operative tumour volume, VolPost: Post operative tumour volume and 
RR: tumour residuum ratio. 
 
 
                    Minimum      Maximum        Mean           Median             SD
  
  
VolPre         4.47 cm³        71.99 cm³       31.995 cm³    30.61 cm³       15.943 
cm³ 
 
VolPost        0.00 cm³        23.27 cm³       3.301 cm³        0.99 cm³        5.094 
cm³ 
 
RR                0.00                 0.74               0.101              0.025             0.159 
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Figure 7.  Scatter plot of preoperative and postoperative 
tumour volume (cm³) 
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            Figure 8.  Scatter plot of residuum ratio 
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         Table 9. Patients’ tumour residuum ratio (RR) 
  
 
Case no. 
RR>0.15 
 (more than 15%) 
RR<0.15  
(less than 15%) 
P1  0 
P2  0 
P3  0 
P4  0.01 
P5  0 
P6  0 
P7 0.26  
P8  0.01 
P9  0 
P10 0.17  
P11 0.23  
P12 0.21  
P13 0.52  
P14  0.14 
P15  0 
P16  0.08 
P17  0.02 
P18 0.17  
P19  0 
P20  0.03 
P21  0.02 
P22  0.04 
P23 0.18  
P24  0 
P25 0.74  
P26 0.36  
P27  0.09 
P28  0 
P29  0 
P30  0 
P31  0 
P32  0 
P33  0.11 
PP4  0.14 
P35  0.02 
P36  0.1 
P37  0.05 
   
Total number 
of cases                9 28 
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3.7. Radiotherapy 
 
Radiotherapy was administered to 25 patients (68%). Cranio-spinal 
radiotherapy and booster dose to the posterior cranial fossa was given to 18 
patients. 10 of them were treated according the PNET-3 protocol (121;157). 5 
patients received Hyperfractionated radiotherapy based on HIT-SIOP PNET 4 
protocol (146) and 3 patients were treated according to the POG 9031 protocol 
(200). 7 patients received only posterior fossa irradiation. In this subset 3 
patients received irradiation of 45Gy, 1 patient received 50 Gy, and 3 patients 
received 55 Gy in accordance with the UKCCSG Infant PNET protocol. All 
patients who received radiotherapy were more than 3 years of age at the time 
of commencement of irradiation. 
 
 
 
3.8. Chemotherapy 
 
Chemotherapy was administered to all 37 patients in this series. At the end of 
the study period 14 (38%) patients had completed their chemotherapy whilst 
10 (27%) patients were still undergoing treatment. Chemotherapy was 
discontinued in 13 (35%) patients due to complications or poor tumour 
response. The chemotherapy regimes used in this study are either currently 
being used or have previously been used in both national and international 
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medulloblastoma clinical trials.  They are based on the following treatment 
protocols: 
 
HART-CNS 2001-06 protocol in 3 cases 
UK Infant PNET protocol in 5 cases 
Packer ’s protocol in 3 cases 
PNET-3 protocol in 6 cases  
PNET-4 protocol in 6 cases  
POG 9031 protocol in 4 cases 
Recurrent PNET protocol in 4 cases 
SFOP Infant Brain Tumour protocol in 6 cases 
 
The protocol of the Hyperfractionated Accelerated Radiotherapy (HART) 
with chemotherapy for metastatic (M1-3) medulloblastoma CNS 2001 06 
protocol consists of vincristine 1.5 mg/m² (maximum 2mg), lomustine 75 mg/ 
m² and cisplatin 70mg/m². 
 
The UK Infant PNET protocol includes:  
1. Induction chemotherapy (6 cycles): cyclophosphamide 90 mg/Kg, 
carboplatin dosed to an AUC of 6.63 mg/ml × min, vincristine 0.05 mg/Kg. 
 
2. Maintenance chemotherapy (4 cycles): vincristine 0.05mg/Kg,  
lomustine (CCNU)  75 mg/m², cisplatin 70 mg/m². 
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The Packer protocol includes vincristine 1.5 mg/m² (up to maximum dose of 2 
mg), lomustine 75 mg/m², cisplatin 75 mg/m². 
 
The chemotherapy regime of the Recurrent PNET protocol (UKCCSG study 
CNS 2000 01) consists of cyclophosphamide 4g/m², thiotepa 900mg/m², 
carboplatin (approximately 550mg/m²). 
 
The POG 9031 protocol consists of: 
1. Pre-radiation chemotherapy: cisplatin 90 mg/m² (3 doses on 7 weeks) and 
etoposide 150mg/m² (6 doses on 7 weeks). 
 
2. Post-radiation chemotherapy (9 cycles): vincristine 1.5 mg/m² and 
cyclophosphamide 1 g/m²; with 40 Gy craniospinal irradiation.  
 
The SFOP infant brain tumours protocol consist of carboplatin 15 mg/Kg, 
etoposide 5 mg/Kg/day, vincristine 0.05 mg/Kg, procarbazine 4 mg/kg/day, 
cisplatin 1 mg/Kg/day, cyclophosphamide 50 mg/Kg. 
 
  
Data regarding the interval time between primary tumour excision and the 
commencement of adjuvant treatment was available in 33 (89%) of 37 cases. 
The mean interval time was 19 days (range: 7 - 53 days, SD: 13, median: 14 
days). 
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Analysis of outcome between tumour volume and radiotherapy or 
chemotherapy type was not performed due to the small number of cases in 
each subgroup.  
 
 
 
3.9. Outcome 
 
Overall Survival 
  
The overall 5-year survival was 59.5%. All deaths (15 cases, 40.5%) occurred 
within 29 months from the time of diagnosis as shown in Figure 9. For the 
subgroup of patients who died the mean survival time was 15.5 months 
(survival time range: 6 - 29 months, SD: 6.5 months).  The cause of death was 
the relapse of medulloblastoma in all cases. The 5-year survival rate was 52% 
for BCH patients and 75% for Necker-IGR patients, which was not 
statistically significant (p= 0.173, log-rank). There was a difference (43%) in 
the rate of complete tumour excision between BCH and Necker-IGR patients. 
6 (24%) of 25 patients of BCH had total excision of medulloblastoma in 
comparison with 8 (67%) of 12 patients of Necker-IGR. There was also a 
large difference (36%) in the rate of patients with metastatic disease at the 
time of diagnosis between BCH and Necker-IGR. 11 (44%) of 25 patients of 
BCH had metastases at the time of diagnosis in comparison with 1 (8%) of 12 
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patients of Necker-IGR. The numbers are too small to determine if these 
differences in outcome between the two centres are statistically significant.  
 
Survival rates were 50% for males and 82% for females, Table 10. The 
difference in survival between males and females suggests a trend towards 
statistical significance (p= 0.061, log-rank), indicating that gender may be a 
prognostic factor for outcome, Figure 10. 
 
The 5-year survival was 63% (11 of 30 patients died) in patients aged 3 years 
or more. Patients under 3 years of age at the time of diagnosis had 5-year 
survival of 43% (4 of 7 patients died). The difference in survival between the 
two age groups was not statistically significant (p= 0 .45, log-rank), Figure 11.  
 
The 5-year survival of patients with and without metastases at the time of 
diagnosis was 42% and 68% respectively (p= 0.08, log-rank, Fisher’s exact 
test: 0.16). In addition, 7 (58%) of 12 patients with metastatic disease at the 
time of diagnosis died. In comparison, 8 (32%) of 25 patients without 
metastatic disease at the time of diagnosis died.  
 
For residual ratio cut off 0.15 (residual tumour volume 15% of primary 
tumour volume), 5 (33%) of 15 patients who died had a RR above 15% and 
the other 10 (67%) had a RR below 15%. Conversely, for the 22 alive patients 
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4 (18%) had a RR above 15% and the other 18 (82%) had a RR below 15% 
(Chi-square: 0.7, Fisher’s exact test: 0.43), Figure 12.  
 
The 5-year survival of patients with residual tumour greater and less than 15% 
of primary medulloblastoma volume was 44.5% and 64% respectively but the 
difference was not statistically significant (log rank, p= 0.27), Figure 13.  
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Figure 9. Overall survival in 37 patients. 
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Figure 10. Overall survival classified by gender 
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Figure 11. Overall survival in 37 patients classified by the age at the time 
of diagnosis of more and less than 3 years. 
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Table 10.   Survival rate by gender 
 
 
Gender        Number of cases      Dead (%)         Alive (%) 
Male                         26                    13   (50)             13  (50) 
               Female                     11                      2   (18)             10  (82) 
               Overall                     37                    15   (40.5)          22 (59.5) 
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Figure 12. Box plot of mortality and residuum ratio cut off 0.15. 
Number 1, 13 and 23 correspond to patients ’number P26, P13 and P25, respectively. 
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                                       Survival time (months) 
 
Figure 13. Overall survival in 37 patients classified by the degree of 
                   tumour excision of more and less than 15% of primary 
tumour volume, p= 0.270. 
 
 
 
 100 
The 5-year survival of patients with residual tumour more and less than 10% 
of primary medulloblastoma volume was 53.8% and 62.5% respectively but 
the difference was not statistically significant (log rank, p= 0.505).  
 
The 5-year survival of patients with residual tumour more and less/equal to 
1.5 cm³ was 50% and 65.2% respectively but the difference was also not 
statistically significant (log rank, p= 0.367), Figure 14. 14 (38%) of 37 
patients had residual tumour equal or less than 1.5 cm³ and the other 23 (62%) 
patients had residual tumour more than 1.5 cm³. 
 
8 (35%) of 23 patients with residual tumour equal to or less than 1.5 cm³ and 7 
(50%) of 14 patients with residual tumour more than 1.5 cm³ died by the end 
of the study (Fisher’s exact test: 0.493). 
  
It is reported in the literature that the absolute residual tumour burden, which 
is likely to be in the range of 1 billion cells (1 cm³), is more critical for 
affective chemotherapy and radiotherapy rather than the percentage of tumour 
removed (55). Statistical analysis was performed using the value of 1 cm³ of 
residual medulloblastoma as a cut off in order to find a difference in outcome 
between patients with residual tumour less or equal to/more than 1 cm³. 5-year 
survival of patients with residual tumour more than and less/equal to 1 cm³ 
was 55.6% and 63.2% respectively but the difference was not statistically 
significant (log rank, p= 0.56). 
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                                        Survival time (months) 
 
 
Figure 14. Overall survival in 37 patients classified by the degree of 
                   residual tumour volume of more or less / equal to 1.5 cm³, 
p= 0.367. 
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The inability of this study to demonstrate a statistically significant correlation 
between the extent of primary excision of medulloblastoma and survival 
prompted further statistical analysis of the data. In particular, an effort was 
made to find the “ideal” cut off point of residuum ratio or/and the volume of 
residual tumour which might assist in producing statistically significant results. 
For that reason histograms, box plot and ROC curve analysis of primary and 
residual tumour volume with mortality was performed, Figures 15-21.  
 
The mean primary (preoperative) medulloblastoma volume of the deceased 
and alive patients were 34 cm³  (range: 9.5 - 57.7 cm³, SD: 15.2 cm³, median: 
34.5 cm³) and 30.6 cm³ (range: 4.5 - 72 cm³, SD: 16.6 cm³, median: 28 cm³), 
respectively. The mean residual (postoperative) medulloblastoma volume of 
the deceased and alive patients were 4.8 cm³  (range: 0 – 23.3 cm³, SD: 6.8 
cm³, median: 1.3 cm³) and 2.2 cm³ (range: 0 - 11.5 cm³, SD: 3.3 cm³, median: 
0.8 cm³) respectively. 
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Figure 15. Histogram of primary tumour volume of deceased patients 
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Figure 16. Histogram of primary tumour volume of alive patients 
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Figure 17. Histogram of residual tumour volume of deceased patients 
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Figure 18. Histogram of residual tumour volume of alive patients 
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Figure 19. Box plot of removed tumour 
volume (cm³) and mortality. 
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Figure 20. Box plot of residuum (post-operative) tumour 
volume (cm³) and mortality. 
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Figure 21. ROC curve of pre- and postoperative (residuum) primary 
tumour volume. 
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The above diagrams demonstrate a significant overlap between primary and 
residual tumour volume distribution in both alive and deceased patients, 
which compromises the definition of a valuable cut off value.  
 
Furthermore, cox regression analysis of many variables including gender, age, 
metastatic status at the time of diagnosis, primary tumour volume, residual 
tumour volume, excised tumour volume and residuum volume cut off was 
performed. This did not show the residual tumour as an independent 
prognostic factor of outcome. However, it showed that age (p= 0.02) and 
metastatic status of patients at the time of diagnosis (p= 0.05) were 
statistically significant prognostic factors. 
 
In summary, in this series of 37 children (26 males and 11 females) with 
medulloblastoma, the overall 5-year survival was 59.5%. For those patients 
who died the mean survival time was 15.5 months (survival time range: 6 - 29 
months, SD: 6.5 months).  The cause of death was relapse of medulloblastoma 
in all cases. 
 
The 5-year survival of patients with residual tumour more and less than 15% 
of primary medulloblastoma volume was 44.5% and 64% respectively but the 
difference was not statistically significant (p= 0.27). Similarly, the 5-year 
survival of patients with residual tumour more than and less than 10% of 
primary medulloblastoma volume was 53.8% and 62.5% respectively (p= 
 111 
0.505); residual tumour more and less/equal than 1.5 cm³ was 50% and 65.2% 
respectively (p= 0.367); and residual tumour more and less/equal than 1 cm³ 
was 55.6% and 63.2% respectively, (p= 0.56). 
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Chapter 4 
 
4.1. Discussion 
 
One of the greatest challenges in neurosurgical oncology is to achieve 
complete excision of a brain tumour. In clinical practice, the neurosurgeon 
strives to achieve complete tumour excision in the safest way possible in order 
to improve the patient’s outcome. However, complete excision of a brain 
tumour may be associated with significant intra- or postoperative morbidity or 
mortality. In the event of a subtotal excision of the primary tumour, the 
neurosurgeon reports the extent of excision as a percentage.  
 
The literature reports a multitude of prognostic factors that contribute to the 
outcome of children with medulloblastoma, Table 3, (44-46;58)  including the 
amount of residual tumour after primary surgical excision (20;44;46;50;52-55).  
 
Although the importance of primary surgical excision of tumour in patients 
with medulloblastoma is widely recognised, the true prognostic significance 
of the extent of surgical resection is still unclear and there is controversy 
regarding whether less than total excision does (52;55;70;121;195) or does not 
(48;49)  improve patient outcome. In addition, there have not been any studies 
in the literature which examine pre- and postoperative medulloblastoma 
volume in relation to outcome. More aggressive surgical resection would 
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seem a logical approach to improve survival in patients with medulloblastoma 
(201). A second look operation may also be considered in patients with 
significant amount of residual tumour after their primary tumour excision.  
 
Many studies have identified the extent of surgical resection as a significant 
outcome predictor and this has prompted neurosurgeons to attempt complete 
tumour resection whenever possible (30;50;70;89;198).  
 
Many neurosurgeons use modern technological adjuncts (CUSA, intra-
operative MR imaging, neuro-navigation) to achieve complete or near 
complete surgical excision of primary medulloblastoma in the safest way 
possible.  
 
Brain shift can occur once the craniotomy has been opened. Intra-operative 
brain shift results in mis-matching between the anatomical and 
radiological/neuro-navigational border of the tumour.  Subsequently, some 
neurosurgeons prefer not to use neuro-navigation for guiding the excision of 
tumour as they consider neuro-navigation to be an unsafe modality. 
Intraoperative brain imaging aims to reduce the effect of brain shift in order to 
help neurosurgeon in excision of tumour in a more accurate hence safer way. 
Also, it helps neurosurgeon to achieve the maximum excision of tumour 
possible by showing the amount of residual tumour left during surgery. In 
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general, despite the operative technological advancements surgery still carries 
a risk of either temporary or permanent neurological deficits (201;202). 
It has been reported that there is an increase in the apparent and likely real 
incidence of posterior fossa mutism which has raised questions about the need 
for total or near total resections in all patients and whether new neurosurgical 
techniques, although theoretically safer, might practically increase the 
morbidity of surgery (99;140).  
 
Postoperative complications and neurological deficits adversely affect quality 
of life and contribute to a delay in commencing adjuvant therapy. Factors that 
may potentially correlate with attempts to achieve complete surgical excision 
of medulloblastoma include the local anatomy (infiltration of brain stem by 
the tumour), the behaviour of the tumour, the surgical approach used, and the 
surgeon’s competence (146;202).  
 
When dealing specifically with medulloblastoma involving the brain stem, the 
goal of gross total resection has been controversial because of the potential for 
surgical morbidity and the absence of data indicating a clear impact on 
progression-free survival (201;202). Additionally, Evans et al have reported 
that the extent of surgical resection had no effect on the duration of survival in 
their cases while controlling for other prognostic factors (48). Packer et al also 
found no statistical evidence of an association between degree of resection 
and event-free survival (49). However, other randomized clinical trials (55;88) 
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have reported that surgical resection of medulloblastoma in children with non-
metastatic disease has improved their outcome. 
In current clinical practice, in the presence of only local disease, subtotal 
tumour resection is defined as the presence of tumour of ≥ 1.5 cm² on 
immediate (within 78 hours from operation) postoperative MRI scan (123). 
The recognition that the clinical outcome of patients with medulloblastoma 
varies according to age at diagnosis, postoperative tumour residuum and 
metastatic stage has led to the development of risk-adapted treatment for 
patients with medulloblastoma (123). At present, average-risk 
medulloblastoma is treated with maximum surgical resection followed by 
chemotherapy and whole neuroaxis radiotherapy (96;121;155;158). Although, 
radiotherapy is a very effective form of treatment for medulloblastoma, it 
damages the surrounding disease-free brain tissue. In the USA, the standard 
neuroaxis radiation dose used to treat children with average-risk 
medulloblastoma has been reduced from 36.0 Gy to 23.4 Gy (123). The 
concurrent introduction of adjuvant chemotherapy has enabled this reduction 
in radiation dose to be made without a negative effect on the number of 
children cured (155;158;199). However a radiation dose of 23.4 Gy is still 
associated with toxic neurological effects especially in children younger than 
8 years, suggesting that there is a need to assess the potential for further 
reduction of that irradiation dose (123).  
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The significant role of surgery in the treatment of patients with 
medulloblastoma has been well recognised since the beginning of the last 
century as it helps to establish histological diagnosis, relieves compression of 
brain stem tumour and relieves CSF obstruction at the level of 4th ventricle 
(obstructive hydrocephalus), all of which are very common occurrences in 
cases of medulloblastoma. However, the value of aggressive tumour resection 
has been difficult to analyze until the mid 1990’s, because the degree of 
tumour excision was based on the subjective assessment of individual 
neurosurgeons (30;48;203;204). Since then, the assessment of the degree of 
tumour excision and the contribution of residual tumour volume to the 
outcome of patients with medulloblastoma were based primarily on 
postoperative CT or MR scans (52;55;89;205).  
 
 However, there are no reports in the literature to correlate the volume of 
residual medulloblastoma with outcome. Although Albright et al found that in 
children who had both M0 stage of disease and were > 3 years old, the 
progression-free survival was better in those with <1.5 cm² of residual tumour 
compared to those with >1.5cm² (p= 0.033), the total volume of residual 
tumour has remained unknown as only a fraction of the residual tumour was 
graded based on one slice of CT or MRI scans. The studied CT or MRI slice 
was that which revealed the larger part of residual tumour (52).   
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The degree of surgical resection in medulloblastoma has never been assessed 
volumetrically in the past. This pilot study investigates the correlation 
between the degree of primary medulloblastoma excision and patient 
mortality and actuarial survival focusing on the neurosurgical aspect of the 
management of patients with medulloblastoma. In conducting the power 
analysis of this study three major issues were considered: 
 
 
1) The absence of any relevant volumetric study which would help in 
calculating the required number of patients for recruitment.  
 
2) The low incidence of medulloblastoma i.e. approximately six cases of 
medulloblastoma were operated per year in BCH (catchment area of 5.5 
million people). 
 
3) Number of patients required for this pilot study to satisfy the scientific 
standards and to be practically achievable. 
 
The above factors resulted in the acceptance of 50% as a value of minimum 
required difference in survival between the subgroups of the study in order to 
detect statistically significant results. There was however no relevant 
information in the literature that would consider the above value as 
unacceptable for this pilot study.  
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It seems obvious to only include patients with non-metastatic disease in the 
study. However, oncologic surgical practice dictates that neurosurgeons 
remove as much tumour as they can safely, regardless of age or M stage. 
Although the benefit of resection has only been statistically confirmed in 
children older than 3 years with M0 stage, resection may well have a clinically 
important, if not statistically significant role (52). In addition, many of the 
patients do not have complete MRI of whole craniospinal axis performed 
preoperatively. In those cases, neurosurgeons did not know if the patients did 
or did not have metastatic disease at the time of operation. This information 
would have guided them to strive for total excision of medulloblastoma in 
children without metastases. Also, for the patients with metastatic disease at 
the time of diagnosis, it remains unknown if the primary medulloblastoma 
tumour is genetically identical to cerebral or spinal metastatic tissue. In the 
event that primary and metastatic tissue are genetically different, their 
response to future adjuvant therapy may also differ.  Which tumour tissue will 
respond better to adjuvant treatment? The answer to this question would guide 
neurosurgeons in deciding on the extent of surgical excision.  
 
In this study, more than one third of patients had total tumour resection and 
another one third of patients had more than 90% excision of primary tumour. 
In three cases (case number: P13, P25, P26) the residual tumour was more 
than 30% of the primary tumour volume. As it is demonstrated in Figures 7, 8 
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and 12, the residuum ratio of P13, P25 and P26 was 0.52, 0.74 and 0.36, 
respectively. Those RR values are unusually high in comparison to the main 
group of the patients. A more likely explanation is that the neurosurgeons 
faced technical difficulties in these particular cases or/and their operative 
performance was not high enough to achieve better degree of tumour excision 
on that operating day.  Figure 7 shows that the residual tumour volume of P25 
was 23.27 cm³ (74% of primary tumour volume). That value is very high and 
further study of patient outcome was performed after excluding it. In that case, 
the mean RR was 0.083 (range: 0 – 0.52, SD: 0.12), which is 0.07 less than 
the original RR value (RR: 0.1, range: 0.0 - 0.7, SD: 0.16). The mean 
preoperative primary medulloblastoma volume was 32 cm³ (range: 4.5 cm³ - 
71.9 cm³, SD: 16.2 cm³). The mean postoperative residual medulloblastoma 
volume was 2.8 cm³ (range: 0.0 cm³ - 11.8 cm³, SD: 3.9 cm³). Furthermore, 
the overall 5-year survival was 61.1% for the group of the 36 patients (P25 is 
not included). In this case there is a 0.6% difference in 5-year survival 
between those two patients’ groups (5-year survival of 37 patients group was 
59.5%) which remains insignificant.  
 
 Interestingly, 2 (P13 and P26) of those 3 patients were still alive at the latest 
follow up (63 and 114 months respectively). This might be explained by the 
fact that they did not present with metastatic disease. In addition, their 
adjuvant treatment it is possible that had cured the local disease, resulting in 
the elimination of the limited surgical excision of tumour as a factor 
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contributing adversely to survival. These cases have uncommonly large 
volumes of residual tumour. They were included in this statistical analysis as 
this reflects the variation of the disease in clinical practice, which poses 
challenges to the medical team.  
 
The overall 5 year survival was 59.5% which is in keeping with the reported 
outcome of patients with medulloblastoma in different clinical trials 
(55;96;121;157;206;207). This study did not show a statistically significant 
difference in 5-year survival (p= 0.27) between the patients with residual 
tumour less and more than 15% of the primary tumour volume. Also, it did 
not show a statistically significant difference in survival between the patients 
with a residual tumour volume more than and equal to or less than 1 cm³ (p= 
0.56) and 1.5 cm³ (p= 0.367).  
 
The reasons for that may be the relatively small number of patients in this 
series. A further reason might be the significant overlapping between the 
primary and residual tumour volume distribution (ROC curve) in both alive 
and deceased patients, which compromised the definition of a valuable cut off 
limit, Figure 21. 
 
It has remained challenging to change the use of the historical value of 1.5 
cm² of residual medulloblastoma as a risk factor for patient outcome. 
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However, Rutkowski et al reported that they stratified patients who were 
included in HIT-SKK ’92 trial based on presence or not of residual tumour 
and the stage of metastatic disease independently from the size of residual 
tumour (89).  In the same year (2005) Grill et al reported that they stratified 
patients based on presence of residual tumour and metastasis at diagnosis in 
the SFOP prospective trial in young children (88).  
 
Grill et al introduced a new risk stratification that was based not only on 
radiological assessment but also on the surgeon’s report. Interestingly, they 
found from a series of 79 cases that 18 children with non-metastatic disease 
had a discrepancy between the operative report and the results of early 
postoperative imaging.  In five patients, the neurosurgeon regarded the 
operation as gross total resection but residual disease was detected on the 
radiological films; and in 13 patients, no residual disease was found on early 
CT or MRI scans, whereas the neurosurgeon had reported macroscopic 
residuum (88).   
 
 
4.1.1. Study limitations 
 
One of the main limitations of this study is the relatively small number of its 
patients. It was extremely difficult to recruit a larger number of patients 
because of: 
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1) Rarity of the tumour 
 
2) The fact that not all patients with medulloblastoma had pre- and immediate 
postoperative MRI of craniospinal axis in that period of time (1999-2006)  
 
3) Unavailability of DICOM data of MRI scans in many cases because 
patients had preoperative MRI scan in district general hospitals or in private 
hospitals.  
 
Every effort was made to avoid bias in this study. The outcome of the 
medulloblastoma, i.e. death, relapse or survival without event was not known 
at the time of selection of patients. The biggest limitation (small number of 
patients) of this study is mainly due to the rarity of the tumour. 
 
It should be stated that patients who only had postoperative imaging were not 
studied because it was impossible to calculate the RR as the primary tumour 
volume was unknown. In these cases, the exclusion of the patients from the 
study due to absence of preoperative MR scan may have affected the results of 
the current study as those patients may have smaller or larger residual volume 
compared with those of studied patients. This also resulted in the exclusion of 
a number of patients where the absolute value (not the RR) of their residual 
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tumour volume could be correlated with their outcome. The data from these 
patients could be used in a future study. 
 
A significant number of patients with medulloblastoma were not included in 
the study (Chart 1) because their pre- and postoperative MR scans were not 
available in DICOM form due to administrative reasons (loss of optic discs on 
which MR scan data was stored, discard of original MR scanners, 
incompatibility between the original optic discs and the available MR scanner 
hardware). These factors resulted in the exclusion of a group of patients with 
potentially different pre- and/or postoperative tumour volumes and RR 
compared to patients of the current series. Subsequently, the current series of 
patients may not be representative of the whole population of patients with 
medulloblastoma. 
 
In addition, there are other sources of bias as follows: 
 
1) The technical limitations of MR scanners affect the quality of obtained MR 
images of the tumours. In particular, the studied images were produced by 1.5 
Tesla MR scanners, which are inferior to 3 Tesla MR scanners from the 
radiological point of view.  
 
2) The quality of tumour enhancement may be affected by the type of contrast 
media and the modality of intravenous administration such as contrast media 
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infusion rate, amount of the contrast media, interval time between the 
injection of the contrast media and MR scanning. Subsequently, there may be 
some radiological / imaging bias between pre- and post operative MR scans as 
the study series patients have not been scanned in the same MR scanner, by 
the same radiographer, and by using the same contrast media.  
 
3) The genetic profile of medulloblastoma may be different between patients, 
and may affect outcome, but this information was not known. 
 
4) A lumbar puncture has not been performed in all patients as it was not part 
of the routine clinical practice during that period of time (1999-2006). 
Subsequently, there is a high possibility that patients with M1 stage to had 
been mistakenly classified as M0 stage. That is a diagnostic bias and may 
have resulted in the undertreatment of some patients. 
 
5) Adjuvant treatment (chemotherapy and radiotherapy) was not identical in 
all patients i.e. chemotherapy or radiotherapy protocols, radiotherapy devices, 
medical or nursing teams (treatment bias). 
 
6) The absence of any calculation of the volume of metastatic disease affects 
the value of the total postoperative tumour volume. However, the calculation 
of the volume of metastases is challenging for the “icing sugar” type of 
leptomeningeal metastases due to its extremely small size.  
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All of the above factors may affect the accuracy of diagnosis, the 
effectiveness of patients treatment and outcome but they could not be 
controlled for this study.  
  
 
4.1.2. Future directions 
 
Further studies into the role of volumetrically assessed residual tumour as a 
risk factor of clinical outcome of children with medulloblastoma will require a 
large number of patients. For example, for a Type I / alpha (α) error with an 
alpha value of 0.05, and for Type II / beta (β) error with beta value of 0.2 and 
powered at 80%, the minimum sample required for each group would be 163  
patients in order to detect a minimum difference of 15% in survival (Hazard 
ratio: 1.51).  This pilot study has shown that 24% (approximately 1:4 patients) 
of patients in this series had residual tumour volume more than 15% of the 
primary tumour volume. It would therefore require an international 
multicentre trial in order to recruit 652 cases in order to obtain a group of 163 
patients with residual tumour of more than 15% of the primary tumour volume.  
 
Many prognostic factors have been reported in the literature that affect patient 
outcome (Table 3). Ideally, a further study about the correlation of volume of 
residual tumour and patient outcome should include patients with absence of 
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metastatic disease matched for prognostic factors such as age group (less or 
more than 3 years), gender, histological variant, genetic profile, and medical 
treatment (chemotherapy or/and radiotherapy).  
 
This study suggests that MR image analysis with segmentation technique 
could feasibly be used in future medulloblastoma trials in order to 
volumetrically assess the volume of primary and residual tumour and correlate 
them with: 
 
1) Incidence of postoperative mutism. 
2) Neuropsychological consequences of tumour excision. 
3) Time to tumour relapse. 
 
 
 
4.2. Conclusion 
 
1. This study has demonstrated the feasibility of performing volumetric 
analysis of residual tumour volume in a multi-centre study. 
 
2. Whilst this study has shown that there is a trend for patients with less 
residual tumour volume to have better outcome than those with more residual 
tumour volume (Figure 13 and 14), that trend was not statistically significant. 
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The number of the patients in this pilot study was not large enough to reach a 
conclusion regarding the correlation between the tumour volume of childhood 
medulloblastomas  and patient outcome. 
 
3. This study has however provided the power calculation for the minimum 
number of patients required in a further study in order to produce statistically 
significant result.  This question can also be prospectively included in future 
therapeutic clinical trials.   
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